Multi-Drug X(2-20) Drugs Rapid Test Panel with/without Adulteration (Urine)

Package Insert

Instruction Sheet for testing of any combination of the following drugs: ACE/AMP/BAR/BZO/BUP/COC/THC/MTD/MET/MDMA/MOP/MQL/OPI/PCP/PPX/TCA/TML/ KET/OXY/COT/EDDP/FYL/K2/6-MAM/MDA/ETG/CLO/LSD/MPD/ZOL/MEP/MDPV/DIA/ZOP/ MCAT/7-ACL/CAF/CFYL/CAT/TRO/ALP/PGB/ZAL/MPRD/CNB/GAB/TZD/CAR/ABP(K3)/QT P/FLX/UR-144(K4)/KRA/TLD/α-PVP/MES/PAP/CIT/FKET/OZP/RPD/TAP/NND/SCOP/MTZ/H MO/ALC

Including Specimen Validity Tests (S.V.T.) for:

Oxidants/PCC, Specific Gravity, pH, Nitrite, Glutaraldehyde, Creatinine and Bleach A rapid test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in human urine. For healthcare professionals including professionals at point of care sites. Immunoassay for *in vitro* diagnostic use only.

[INTENDED USE]

The Multi-Drug Rapid Test Panel is a rapid chromatographic immunoassay for the qualitative detection of multiple drugs and drug metabolites in human urine at the following cut-off concentrations:

Test	Calibrator	Cut-off (ng/mL)
Acetaminophen (ACE)	Acetaminophen	5,000
Amphetamine (AMP)	d-Amphetamine	1,000/500/300
Barbiturates (BAR)	Secobarbital	300/200
Benzodiazepines (BZO)	Oxazepam	500/300/200/100
Buprenorphine (BUP)	Buprenorphine	10/5
Cocaine (COC)	Benzoylecgonine	1,500/300/200/150/100
Marijuana (THC)	11-nor-Δ ⁹ -THC-9 COOH	300/200/150/50/30/25/ 20
Methadone (MTD)	Methadone	300/200
Methamphetamine (MET)	d-Methamphetamine	1,000/500/300/200
Methylenedioxyme- thamphetamine(MDMA)	d,l-Methylenedioxymethamphetamine	1,000/500/300
Morphine/Opiate (MOP/OPI)	Morphine	300/200/100
Methaqualone (MQL)	Methaqualone	300
Meperidine (MPRD)	Normeperidine	100
Opiate (OPI)	Morphine	2,000/1,000
Phencyclidine (PCP)	Phencyclidine	50/25
Propoxyphene (PPX)	Propoxyphene	300
Tricyclic Antidepressants (TCA)	Nortriptyline	1,000/500/300
Tramadol (TML)	Cis-Tramadol	500/300/200/100
Ketamine (KET)	Ketamine	1,000/500/300/100
Oxycodone (OXY)	Oxycodone	300/100
Cotinine (COT)	Cotinine	500/300/200/100/50/10
2-ethylidene-1,5-dimethyl-	2-ethylidene-1,5-dimethyl-	300/100
3,3-diphenylpyrrolidine (EDDP)	3,3-diphenylpyrrolidine	300/100
Fentanyl (FYL)	Norfentanyl	20/10
Fentanyl (FYL)	Fentanyl	300/200/100
Synthetic Marijuana (K2)	JWH-018、JWH-073	50/30/25
6-Monoacetylmorphine (6-MAM)	6-MAM	10
(±) 3,4-Methylenedioxy- Amphetamine (MDA)	(±) 3,4-Methylenedioxy- Amphetamine	500
Ethyl- β-D-Glucuronide (ETG)	Ethyl- β -D-Glucuronide	1,500/1,000/500/300
Clonazepam (CLO)	Clonazepam	400/150
Lysergic Acid Diethylamide (LSD)	Lysergic Acid Diethylamide	50/20/10
Methylphenidate (MPD)	Methylphenidate	300/150
Methylphenidate (MPD)	Ritalin acid	1,000
Zolpidem (ZOL)	Zolpidem	50/25
Mephedrone (MEP)	Mephedrone	500/100
3, 4-methylenedioxy- pyrovalerone (MDPV)	3, 4-methylenedioxypyrovalerone	1,000/500/300
Diazepam (DIA)	Diazepam	300/200
Zopiclone (ZOP)	Zopiclone	300/50
Methcathinone (MCAT)	S(-)-Methcathinone	500

7-Aminoclonazepam (7-ACL)	7-Aminoclonazepam	300/200/100
Carfentanyl (CFYL)	Carfentanyl	500/250
Cannabinol (CNB)	Cannabinol	500
Caffeine (CAF)	Caffeine	1,000
Cathine (CAT)	(+)-Norpseudoephedrine	150
Tropicamide (TRO)	Tropicamide	350
Alprazolam (ALP)	Alprazolam	100
Pregabaline (PGB)	Pregabaline	50,000/500
Gabapentin (GAB)	Gabapentin	2,000/5000
Zaleplon (ZAL)	Zaleplon	100
Carisoprodol (CAR)	Carisoprodol	2,000/1,000/500
AB-PINACA/K3 (ABP/K3)	AB-PINACA	10
Quetiazepam (QTP)	Quetiazepam	1,000
Fluoxetine (FLX)	Fluoxetine	500
UR-144/K4	UR-144 5-Pentanoic acid	25
Kratom (KRA)	Mitragynine	300
Tilidine (TLD)	Nortilidine	50
Trazodone (TZD)	Trazodone	200
Alpha-Pyrrolidinovalerophenone (α-PVP)	Alpha-Pyrrolidinovalerophenone	2,000/1,000/500/300
Mescaline (MES)	Mescaline	300/100
Papaverine (PAP)	Papaverine	500
Citalopram (CIT)	Citalopram	500
Fluoketamine (FKET)	Fluoketamine	1,000
Olanzapine (OZP)	Olanzapine	1,000
Risperidone (RPD)	Risperidone	150
Tapentadol (TAP)	Tapentadol	1,000
N,N-Dimethyltryptamine (NND)	N,N-Dimethyltryptamine	1,000
Scopolamine (SCOP)	Scopolamine	500
Mirtazapine (MTZ)	Desmethylmirtazapine	500
Hydromorphone (HMO)	Hydromorphone	500/300/250

Test	Calibrator	Cut-off
Alcohol(ALC)	Alcohol	0.02%

Configurations of the Multi-Drug Rapid Test Panel come with any combination of the above listed drug analytes with or without S.V.T. This assay provides only a preliminary test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

[SUMMARY OF ADULTERATION]

Adulteration is the tampering of a urine specimen with the intention of altering the test results. The use of adulterants can cause false negative results in drug tests by either interfering with the screening test and/or destroying the drugs present in the urine. Dilution may also be employed in an attempt to produce false negative drug test results.

One of the best ways to test for adulteration or dilution is to determine certain urinary characteristics such as pH, specific gravity and creatinine and to detect the presence of oxidants/PCC, nitrites or glutaraldehyde in urine.

[PRINCIPLE (FOR DOA TESTS EXCLUDING ALCOHOL)]

During testing, a urine specimen migrates upward by capillary action. A drug, if present in the urine specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test region of the specific drug dipstick. The presence of drug above the cut-off concentration will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test region.

A drug-positive urine specimen will not generate a colored line in the specific test region of the dipstick because of drug competition, while a drug-negative urine specimen will generate a line in the test region because of the absence of drug competition.

To serve as a procedural control, a colored line will always appear at the control region, indicating that proper volume of specimen has been added and membrane wicking has occurred.

[PRINCIPLE OF ADULTERATION]

Oxidants/PCC (Pyridiniumchlorochromate) tests for the presence of oxidizing agents such as bleach and hydrogen peroxide. Pyridiniumchlorochromate (sold under the brand name Urine

Luck) is a commonly used adulterant.² Normal human urine should not contain oxidants of PCC. **Specific gravity** tests for sample dilution. The normal range is from 1.003 to 1.030. Values outside this range may be the result of specimen dilution or adulteration.

pH tests for the presence of acidic or alkaline adulterants in urine. Normal pH levels should be in the range of 4.0 to 9.0. Values outside of this range may indicate the sample has been altered.

Nitrite tests for commonly used commercial adulterants such as Klear and Whizzies. They work by oxidizing the major cannabinoid metabolite THC-COOH.³ Normal urine should contain no trace of nitrite. Positive results generally indicate the presence of an adulterant.

Glutaraldehyde tests for the presence of an aldehyde. Adulterants such as Urin Aid and Clear Choice contain glutaraldehyde which may cause false negative results by disrupting the enzyme used in some immunoassay tests.³ Glutaraldehyde is not normally found in urine; therefore, detection of glutaraldehyde in a urine specimen is generally an indicator of adulteration.

Creatinine is a waste product of creatine; an amino-acid contained in muscle tissue and found in urine. A person may attempt to foil a test by drinking excessive amounts of water or diuretics such as herbal teas to flush the system. Creatinine and specific gravity are two ways to check for dilution and flushing, which are the most common mechanisms used in an attempt to circumvent drug testing. Low Creatinine and specific gravity levels may indicate dilute urine. The absence of Creatinine (<5 mg/dL) is indicative of a specimen not consistent with human urine.

Bleach tests for the presence of bleach. Bleach refers to a number of chemicals which remove color, whiten or disinfect, often by oxidation, Bleaches are used as household chemicals to whiten clothes and remove stains and as disinfectants. Normal human urine should not contain bleach.

[PRINCIPLE (FOR ALCOHOL)]

The urine Alcohol Rapid Test Panel consists of a plastic strip with a reaction pad attached at the tip. On contact with alcohol, the reaction pad will change colors depending on the concentration of alcohol present. This is based on the high specificity of alcohol oxidase for ethyl alcohol in the presence of peroxidase and enzyme substrate such as TMB.

[REAGENTS(FOR DOA TESTS EXCLUDING ALCOHOL)]

Each test line contains anti-drug mouse monoclonal antibody and corresponding drug-protein conjugates. The control line contains goat anti-rabbit IgG polyclonal antibodies and rabbit IgG.

[REAGENTS (FOR ALCOHOL)]

Tetramethylbenzidine, Alcohol Oxidase, Peroxidase

[S.V.T REAGENTS]

KO:V:: KEAGERIO		
Adulteration Pad	Reactive indicator	Buffers and non-reactive ingredients
Creatinine	0.04%	99.96%
Nitrite	0.07%	99.93%
Bleach	0.39%	99.61%
Glutaraldehyde	0.02%	99.98%
рН	0.06%	99.94%
Specific Gravity	0.25%	99.75%
Oxidants / PCC	0.36%	99.64%

[PRECAUTIONS]

- For healthcare professionals including professionals at point of care sites.
- Immunoassay for in vitro diagnostic use only. The test should remain in the sealed pouch until use.
- All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.
- The used test should be discarded according to local regulations.

[STORAGE AND STABILITY]

Store as packaged in the sealed pouch at 2-30°C. The test is stable through the expiration date printed on the sealed pouch. The Test must remain in the sealed pouch until use. **DO NOT FREEZE.** Do not use beyond the expiration date.

[SPECIMEN COLLECTION AND PREPARATION]

Urine Assay

The urine specimen should be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be centrifuged, filtered, or allowed to settle to obtain a clear specimen for testing.

Specimen Storage

Urine specimens may be stored at 2-8°C for up to 48 hours prior to testing. For prolonged storage, specimens may be frozen and stored below -20°C. Frozen specimens should be thawed and mixed well before testing. When testing cards with S.V.T. or Alcohol storage of urine specimens should not exceed 2 hours at room temperature or 4 hours refrigerated prior to testing.

[MATERIALS]

Test Panels

Materials Provided

- Package Insert
- · Adulteration Color Chart (when applicable)


Materials Required But Not Provided

 Timer · Specimen collection containers

[DIRECTIONS FOR USE]

Allow the test, urine specimen, and/or controls to reach room temperature (15-30°C) prior

- 1. Bring the pouch to room temperature before opening it. Remove the test panel from the sealed pouch and use it within one hour.
- 2. Remove the cap.
- 3. With the arrow pointing toward the urine specimen, immerse the test panel vertically in the urine specimen for at least 10 to 15 seconds. Immerse the dipstick to at least the level of the wavy lines, but not above the arrow on the test panel.
- 4. Replace the cap and place the test panel on a non-absorbent flat surface.
- 5. Start the timer and wait for the colored line(s) to appear.
- 6. Read the adulteration strips and alcohol strip between 3-5 minutes according to color chart provided separately/on foil pouch. Refer to your Drug Free Policy for guidelines on adulterated specimens. We recommend not to interpret the drug test results and either retest the urine or collect another specimen in case of any positive result for any adulteration test.
- 7. The drug strip result should be read at 5 minutes. Do not interpret the result after 10 minutes.



[INTERPRETATION OF RESULTS]

(Please refer to the illustration above)

NEGATIVE:* A colored line appears in the control region (C) and another colored line appears in the test region (T). This negative result means that the concentrations in the urine sample are below the designated cut-off levels for a particular drug tested.

*NOTE: The shade of the colored lines(s) in the test region (T) may vary. The result should be considered negative whenever there is even a faint line.

POSITIVE: A colored line appears in the control region (C) and no line appears in the test region (T). The positive result means that the drug concentration in the urine sample is greater than the designated cut-off for a specific drug.

INVALID: No line appears in the control region (C). Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Read the directions again and repeat the test with a new test. If the result is still invalid, contact your manufacturer.

[INTERPRETATION OF RESULTS (S.V.T/ ADULTERATION)]

(Please refer to the color chart)

Semi-Quantitative results are obtained by visually comparing the reacted color blocks on the strip to the printed color blocks on the color chart. No instrumentation is required.

[INTERPRETATION OF RESULTS (ALCOHOL STRIP)]

Negative: Almost no color change by comparing with the background. The negative result indicates that the urine alcohol level is less than 0.02%.

Positive: A distinct color developed all over the pad. The positive result indicates that the urine alcohol concentration is 0.02% or higher.

Invalid: The test should be considered invalid if only the edge of the reactive pad turned color

that might be ascribed to insufficient sampling. The subject should be re-tested. Besides, if the color pad has a blue color before applying urine sample, do not use the test.

[QUALITY CONTROL]

A procedural control is included in the test. A line appearing in the control region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

Control standards are not supplied with this kit. However, it is recommended that positive and negative controls be tested as good laboratory practice to confirm the test procedure and to verify proper test performance.

[LIMITATIONS]

- 1. The Multi-Drug Rapid Test Panel provides only a qualitative, preliminary result. A secondary analytical method must be used to obtain a confirmed result. Gas Chromatography /Mass Spectrometry (GC/MS) is the preferred confirmatory method. 4,5
- 2. There is a possibility that technical or procedural errors, as well as interfering substances in the urine specimen may cause erroneous results.
- 3. Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.
- 4. A positive result does not indicate level or intoxication, administration route or concentration
- 5. A negative result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cut-off level of the test.
- 6. This test does not distinguish between drugs of abuse and certain medications.
- 7. A positive test result may be obtained from certain foods or food supplements.

[S.V.T/ ADULTERATION LIMITATIONS]

- 1. The adulteration tests included with the product are meant to aid in the determination of abnormal specimens. While comprehensive, these tests are not meant to be an "all-inclusive" representation of possible adulterants.
- 2. Oxidants/PCC: Normal human urine should not contain oxidants or PCC. The presence of high levels of antioxidants in the specimen, such as ascorbic acid, may result in false negative results for the oxidants/PCC pad.
- 3. Specific Gravity: Elevated levels of protein in urine may cause abnormally high specific gravity values.
- 4. Nitrite: Nitrite is not a normal component of human urine. However, nitrite found in urine may indicate urinary tract infections or bacterial infections. Nitrite levels of >20 mg/dL may produce false positive glutaraldehyde results.
- 5. Glutaraldehyde: is not normally found in urine. However certain metabolic abnormalities such as ketoacidosis (fasting, uncontrolled diabetes or high protein diets) may interfere with
- 6. Creatinine: Normal Creatinine levels are between 20 and 350 mg/dL. Under rare conditions, certain kidney diseases may show dilute urine.
- 7. Bleach: Normal human urine should not contain bleach. The presence of high levels of bleach in the specimen may result in false negative results for the bleach pad.
- 8. pH: Normal pH levels are between 4.0 and 9.0.

[PERFORMANCE CHARACTERISTICS] Accuracy

% Agreement with GC/MS

	ACE	AMP	AMP	AMP	BAR	BAR	BZO	BZO	BZO	BZO	BUP
	5,000	1,000	500	300	300	200	500	300	200	100	10
Positive Agreement	93.5%	98.1%	99.1%	99.1%	96.1%	95.3%	98.2%	98.4%	99.2%	99.2%	99.1%
Negative Agreement	98.6%	97.9%	98.6%	98.5%	98.6%	97.9%	97.8%	99.2%	98.4%	97.5%	>99.9%
Total Results	97.0%	98.0%	98.8%	98.8%	97.6%	96.8%	98.0%	98.8%	98.8%	98.4%	99.6%
	BUP	COC	COC	COC	COC	THC	THC	THC	THC	THC	MTD
	5	300	200	150	100	300	150	50	25	20	300
Positive Agreement	99.1%	98.2%	>99.9%	98.3%	99.2%	95.5%	94.5%	97.9%	96.9%	94.8%	98.9%
Negative Agreement	>99.9%	97.8%	>99.9%	97.0%	97.0%	98.1%	97.5%	98.1%	97.4%	99.3%	98.8%
Total Results	99.6%	98.0%	100.0%	97.6%	98.0%	97.2%	96.4%	98.0%	97.2%	97.6%	98.8%

	MTD 200	MET 1,000	MET 500	MET 300	MDMA 1,000	MDMA 500	MDMA 300	MOP/ OPI 300	MOP/ OPI 100	MQL 300	OPI 2,000
Positive Agreement	98.9%	96.2%	97.6%	97.8%	98.0%	98.1%	98.1%	95.0%	97.0%	89.8%	96.7%
Negative Agreement	98.7%	97.1%	97.0%	97.5%	99.3%	99.3%	99.3%	95.3%	96.6%	93.2%	93.8%
Total Results	98.8%	96.8%	97.2%	97.6%	98.8%	98.8%	98.8%	95.2%	96.8%	92.0%	95.2%
	DOD	DD)/	TO 4	TO 4	T1.41	T1.41	T1.41	WET	WET	VET	VET
	PCP 25	PPX 300	TCA 1,000	TCA 500	TML 100	TML 200	TML 300	KET 1,000	KET 500	KET 300	KET 100
Positive Agreement	92.4%	96.0%	94.8%	94.9%	88.2%	88.2%	88.0%	97.5%	97.6%	96.7%	96.0%
Negative Agreement	96.8%	94.0%	91.6%	92.1%	92.4%	96.2%	96.2%	98.2%	98.2%	97.5%	97.3%
Total Results	95.2%	94.8%	92.8%	93.2%	90.8%	93.2%	93.2%	98.0%	98.0%	97.2%	96.8%
	OXY	OXY	COT	COT	COT	COT	COT	EDDP	EDDP	FYL	FYL
	100	300	500	200	100	50	10	300	100	20	10
Positive Agreement	97.7%	96.5%			97.9%	96.7%			96.9%	98.8%	98.8%
Negative Agreement	99.4%	99.4%	96.1%	97.5%	98.1%	97.5%	98.1%	99.4%	96.7%	99.4%	99.4%
Total Results	98.8%	98.4%	96.0%	97.2%	98.0%	97.2%	98.0%	98.8%	96.8%	99.2%	99.2%
	,										
	K2 50	K2 30	6-MAM 10	MDA 500	ETG 500	ETG 1,000	CLO 400	CLO 150	LSD 10	LSD 20	LSD 50
Positive Agreement	97.5%	97.6%	97.7%	98.1%	97.6%	95.3%	97.1%	99.0%	94.3%	94.3%	94.1%
Negative Agreement	98.2%	98.8%	98.1%	97.9%	99.4%	99.4%	99.3%	98.6%	98.5%	98.5%	98.5%
Total Results	98.0%	98.4%	98.0%	98.0%	98.8%	98.0%	98.4%	98.8%	97.0%	97.0%	97.0%
								L			
	MPD 300	MPD	ZOL	DIA 300	DIA 200	ZOP	MCAT		7-ACL	7-ACL	CFYL
Positive	94.6%	94.6%	50 90.9%		98.4%	50 86.4%	500 90.9%	300 94.1%	200 94.6%	100 94.7%	500 94.7%
Agreement Negative Agreement	98.4%	98.4%	97.1%	99.2%	99 2%	97.2%	95.0%	97.7%	97.6%	97.5%	98.6%
					00.270						
Total	97.0%	97.0%	95.6%		98.8%			96.2%	96.2%	96.2%	97.3%
	97.0%	97.0%	95.6%					96.2%	96.2%		97.3%
Total	CAF	CAT	TRO	98.8% MDPV	98.8% MDPV	94.6% MEP	94.1% ALP	ABP/	α-PVP	96.2% CNB	MPRD
Total Results	1	1	TRO 350	98.8% MDPV 1,000	98.8%	94.6% MEP 100	94.1% ALP 100	ABP/ K3 10		96.2%	
Total Results Positive Agreement Negative	CAF 1,000	CAT 150	TRO 350 92.0%	98.8% MDPV 1,000 93.3%	98.8% MDPV 500	94.6% MEP 100 90.5%	94.1% ALP 100	ABP/ K3 10 92.0%	α-PVP 1,000 92.1%	96.2% CNB 500	MPRD 100
Total Results Positive Agreement	CAF 1,000 91.3%	CAT 150 90.5% 97.3%	TRO 350 92.0% 97.0%	98.8% MDPV 1,000 93.3% 98.6%	98.8% MDPV 500 93.1% 98.3%	94.6% MEP 100 90.5% 97.0%	94.1% ALP 100 90.9% 97.4%	ABP/ K3 10 92.0% 97.1%	α-PVP 1,000 92.1% 96.8%	96.2% CNB 500 95.8%	MPRD 100 95.0% 94.2%
Total Results Positive Agreement Negative Agreement Total	CAF 1,000 91.3% 95.7%	CAT 150 90.5% 97.3%	TRO 350 92.0% 97.0%	98.8% MDPV 1,000 93.3% 98.6%	98.8% MDPV 500 93.1% 98.3%	94.6% MEP 100 90.5% 97.0%	94.1% ALP 100 90.9% 97.4%	ABP/ K3 10 92.0% 97.1%	α-PVP 1,000 92.1% 96.8%	96.2% CNB 500 95.8% 97.6%	MPRD 100 95.0% 94.2%
Total Results Positive Agreement Negative Agreement Total	CAF 1,000 91.3% 95.7%	CAT 150 90.5% 97.3%	TRO 350 92.0% 97.0% 95.6% UR-144	98.8% MDPV 1,000 93.3% 98.6%	98.8% MDPV 500 93.1% 98.3%	94.6% MEP 100 90.5% 97.0%	94.1% ALP 100 90.9% 97.4% 95.9%	ABP/ K3 10 92.0% 97.1%	α-PVP 1,000 92.1% 96.8%	96.2% CNB 500 95.8% 97.6%	MPRD 100 95.0% 94.2%
Total Results Positive Agreement Negative Agreement Total Results Positive	CAF 1,000 91.3% 95.7% 94.6%	CAT 150 90.5% 97.3% 95.8%	TRO 350 92.0% 97.0% 95.6%	98.8% MDPV 1,000 93.3% 98.6% 97.0%	98.8% MDPV 500 93.1% 98.3% 96.6%	94.6% MEP 100 90.5% 97.0% 95.4% GAB 2,000	94.1% ALP 100 90.9% 97.4% 95.9% MOP/ OPI 200	ABP/ K3 10 92.0% 97.1% 95.8% ETG 300	α-PVP 1,000 92.1% 96.8% 95.0%	96.2% CNB 500 95.8% 97.6% 96.9%	MPRD 100 95.0% 94.2% 94.4%
Total Results Positive Agreement Negative Agreement Total Results	CAF 1,000 91.3% 95.7% 94.6% PGB 50,000	CAT 150 90.5% 97.3% 95.8% TZD 200	TRO 350 92.0% 97.0% 95.6% UR- 144 25 97.1%	98.8% MDPV 1,000 93.3% 98.6% 97.0% ZAL 100 95.2%	98.8% MDPV 500 93.1% 98.3% 96.6% MES 100	94.6% MEP 100 90.5% 97.0% 95.4% GAB 2,000 92.3%	94.1% ALP 100 90.9% 97.4% 95.9% MOP/ OPI 200 95.0%	ABP/ K3 10 92.0% 97.1% 95.8% ETG 300 98.8%	α-PVP 1,000 92.1% 96.8% 95.0% α-PVP 500	96.2% CNB 500 95.8% 97.6% 96.9% TLD 50	MPRD 100 95.0% 94.2% 94.4% QTP 1,000

	PAP 500		RA 300	CAR 2,000		FLX 500		.2 .5	CI7		FKE 1,00		RPD 150		FYL 100	FYL 200	CFYL 250
Positivo	300	3	000	2,000	+	300		.5	300	U	1,00	U	130	╁	100	200	230
Positive Agreement	96.9%	95	.7%	95.0%	6 9 ⁻	7.1%	97.	6%	93.3	8%	96.7	% 9	3.3%	9	8.8%	97.5%	94.7%
Negative Agreement	98.0%	98	.3%	94.2%	6 9	6.6%	98.	2%	95.5	5%	97.0	% 9	5.5%	9	9.4%	99.4%	98.6%
Total Results	97.6%	97	.6%	94.4%	6 9	6.8%	98.	0%	94.8	8%	96.9	% 9	4.8%	9	9.2%	98.8%	97.3%
		Т	1450	10-			I		' D		D) (D)	_		_		0000	
	PGB 500		MES 300	OZ 1,0		MDF 30		α-P\ 2,00			PVP 00		AP 000		,000	SCOP 500	MTZ 500
Positive Agreement	95.2%	6 9	95.8%	95.8	3%	93.8	3%	86.8	3%	92	.1%	94.	4%	96	6.7%	93.5%	93.3%
Negative Agreement	96.3%	6 9	97.6%	97.6	5%	97.1	%	96.8	3%	95	.2%	98.	2%	97	7.0%	98.6%	95.6%
Total Results	96.0%	6 9	96.9%	96.9	9%	96.1	%	93.0)%	94	.0%	96.	7%	96	6.9%	97.0%	94.9%
	007	T =-		TUO	-		Τ.		T ~		-	2.0		. 1	TO 4	045	E) (I
	300		HC 200	THC 30		MEP 500		IPD 50)PI 000		CP i0	TM 500		TCA 300		
Positive Agreement	97.7%	93	.4%	97.9%	6 9	5.2%	91	.9%	95.	.9%	92.	3%	92.9	%	94.9%	6 90.0%	6 97.0%
Negative Agreement	97.5%	97	.5%	98.1%	6 9	8.5%	98	3.4%	93.	.8%	96.	9%	98.1	%	92.19	6 98.1%	6 98.99
Total Results	97.6%	96	.0%	98.0%	6 9	7.7%	96	6.0%	94.	.8%	95.	2%	96.9	%	93.2%	6 95.8%	6 98.69
														_			
)	HMC		MC 500		ИЕТ 200		CAR 500		COC 1,500		.500	1	ZOP 300	ZOL 25	GAB 5,000
	HMC 250	, J	300				-00		JUU	+	،,٥٥١	+	,500	+	UUU	20	5,000
Positive Agreement	250 93.8°		91.7		.79	6 9	7.6%	6 9	0.0%	6	92.0%	6 9	7.7%	90	0.9%	90.9%	93.19
Agreement Negative	93.89	%		% 91			7.6% 7.0%		0.0%	+	92.0%		7.7% 9.4%	-		90.9% 97.1%	
Agreement	93.89 97.59	%	91.7	% 91 % 98	1.79	6 9		6 9		% !		6 99		97	7.2%		98.6%
Agreement Negative Agreement	93.89 97.59	%	91.7	% 91 % 98 % 96	3.79 3.79 3.19	6 9 ⁻	7.0% 7.2%	6 9. 6 9	12.3%	% !	98.3% 95.2%	6 98 6 98	9.4%	97	7.2%	97.1%	98.6%
Agreement Negative Agreement	93.89 97.59 s 96.19	% %	91.7° 98.7° 96.1°	% 91 % 98 % 96	3.79 3.19 gre	6 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	7.0% 7.2% nt w	6 9 6 9	2.3% 11.7%	% :	98.3% 95.2% rcial	6 98 6 98	9.4%	95	7.2% 5.7%	97.1% 95.6%	98.6%
Agreement Negative Agreement	93.89 97.59 s 96.19	%	91.7° 98.7° 96.1°	% 91 % 98 % 96 % A	3.79 3.19 agre	6 9 9 emer	7.0% 7.2% nt w	6 9 9 ith C	12.3% 11.7% Com	% ! % !	98.3% 95.2% rcial	6 98	9.4% 8.8%	97 98	7.2% 5.7%	97.1% 95.6% THC	98.6% 96.9% MPD
Agreement Negative Agreement	93.89 97.59 s 96.19	%	91.7° 98.7° 96.1° AMP	% 91 % 98 % 96 % A	3.7% 3.1% gre AR	6 91 6 91 8 B2 50	7.0% 7.2% nt w ZO	6 9 6 9	12.3% 11.7% Com	% ! % !	98.3% 95.2% rcial OC 00/	6 98 Kit CC 1,5	9.4% 8.8% OC 00/	97 95 Th	7.2% 5.7% HC	97.1% 95.6% THC 300/	98.6% 96.9% MPD 1,000
Agreement Negative Agreement	93.89 97.59 s 96.19	%	91.7° 98.7° 96.1° AMP 1,000 500/	% 91 % 98 % 96 % A	3.79 3.19 agre	6 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	7.0% 7.2% nt w ZO 00/	6 9 9 ith C	12.3% 11.7% Com	% ! % !	98.3% 95.2% rcial	6 98 Kit CC 1,5	9.4% 8.8% OC 00/	97 95 Th	7.2% 5.7% HC	97.1% 95.6% THC 300/ 200/30/	98.69 96.99 MPD 1,000 300/
Agreement Negative Agreement	93.89 97.59 s 96.19	%	91.7° 98.7° 96.1° AMP	% 91 % 98 % 96 % A	3.7% 3.1% gre AR	6 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	7.0% 7.2% nt w ZO 00/ 00/	6 9 9 ith C	12.3% 11.7% Com	% ! % !	98.3% 95.2% rcial OC 00/	6 98 Kit CC 1,5	9.4% 8.8% OC 00/	97 95 Th	7.2% 5.7% HC	97.1% 95.6% THC 300/	98.6% 96.9% MPD 1,000
Agreement Negative Agreement Total Result	93.89 97.59 s 96.19	%	91.7° 98.7° 96.1° AMP 1,000 500/ 300	% 91 % 98 % 96 % A	3.7% 3.1% agree AR 200/	6 9° 6 9° 8 EMB2 50 30 20 10	7.0% 7.2% nt w ZO 000/ 000/ 000/	6 9 6 9 ith C	02.3% 01.7% Com JP 0/5	me C: 3:	98.3% 95.2% rcial OC 00/ 00	6 98 Kit CC 1,5	9.4% 8.8% OC 00/ 50	95 95 TH	7.2% 5.7% HC	97.1% 95.6% THC 300/ 200/30/	98.69 96.99 MPD 1,000 300/
Agreement Negative Agreement Total Result Positive Agreement Negative	93.8° 97.5° s 96.1° ACE 5,000	% % %	91.7' 98.7' 96.1' AMP 1,000 500/ 300	% 98 98 96 % A 9 98 96 96 96 96 96 96 96 96 96 96 96 96 96		6 9° 8emer B2 50 30 20 10 6 > 99	7.0% 7.2% nt w ZO 00/ 00/ 00/ 00/	6 9 9 ith C BU 10.	12.3% 11.7% Comp JP J/5	me C:31 1	98.3% 95.2% rcial OC 00/ 00	6 99 Kit CC 1,5 20 15	9.4% 8.8% 00C 000/ 000/	97 98 TH 150 2	7.2% 5.7% HC 0/50/	97.1% 95.6% THC 300/ 200/30/	98.69 96.99 MPD 1,000 300/
Agreement Negative Agreement Total Result Positive Agreement Negative Agreement	250 93.8° 97.5° s 96.1° ACE 5,000	% % % % % % % % % % % % % % % % % % %	91.7' 98.7' 96.1' AMPP 1,000 500/ 300	91 98 98 98 98 98 98 98 98 98 98 98 98 98		B2 B2 SC 3C 2C 10 66 > 99	7.0% 7.2% nt w ZO 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/	ith C BU 10.	22.3% 11.7% Com JP J/5	me C: 3: 1	98.39 95.29 rcial OC 00/ 000	Kit CC 1,5 20 15	9.4% 8.8% 00C 000/ 500	97 95 TH 150 2	7.2% 5.7% HC 0/50/ 25 2	97.1% 95.6% THC 300/ 200/30/ 20	98.69 96.99 MPD 1,000 300/ 150
Agreement Negative Agreement Total Result Positive Agreement Negative Agreement	2500 93.8° 97.5° \$ 96.1° ACE 5,000 * * * * * * * *	% % % % % % % % % % % % % % % % % % %	91.7' 98.7' 96.1' AMP 1,000 500/ 300	91 98 98 98 98 98 98 98 99 99 99 99 99 99		66 99 82 82 83 84 85 86 87 86 87 87 87 87 87 87 87	7.0% 7.2% mt w 2O 00/ 00/ 00/ 00/ 00/ 0.9%	6 9 9 ith C BU 10 >99.	22.3% 11.7% Comp JP J/5 .9%	me Cl 31 1 >99 >99	98.39 95.29 rcial OC 00/ 00 93.9%	Kit CC 1,5 20 15	9.4% 8.8% 00C 00/ 00/ 00/ * * * * *	97 95 150 2 >99 >99	77.2% 55.7% HC h/50/ 25 2	97.1% 95.6% THC 300/ 200/30/ 20	98.69 96.99 MPD 1,000 300/ 150
Agreement Negative Agreement Total Result Positive Agreement Negative Agreement	250 93.8° 97.5° s 96.1° ACE 5,000	% % % % % % % % % % % % % % % % % % %	91.7' 98.7' 96.1' AMPP 1,000 500/ 300	% AA BA 30 / 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	.gre AR 000 00 0.9%	B2250 300 200 100 66 > 99	7.0% 7.2% nt w ZO 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/	ith C BU 10.	22.3% 11.7% Com JP J/5	me C: 3: 1 >99 >99	98.39 95.29 rcial OC 00/ 000	Kit CC 1,5 200 15	9.4% 8.8% 00C 000/ 500	97 95 150 2 >99 >99 M	77.2% 55.7% HC 0/50/ 55 2	97.1% 95.6% THC 300/ 200/30/ 20	98.69 96.99 MPD 1,000 300/ 150
Agreement Negative Agreement Total Result Positive Agreement Negative Agreement	250 93.8° 97.5° 97.5° 8 96.1° ACE 5,000	% % % % % % % % % % % % % % % % % % %	91.7' 98.7' 96.1' AMP 11,000 500/ 300 -99.9'	% AA AB B 30 30 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3		B2250 300 200 100 66 > 99	7.0% 7.2% nt w 2O 00/ 00/ 00/ 00/ 0.9% 1.9%	ith C BU 10.	22.3% 11.7% Comply 1.9% .9% .9%	me C: 3: 1 >99 >99	98.39 95.29 rcial OC 00/ 00 00 93.9%	Kit CC 1,5 20 15	9.4% 8.8% 00C 00/ 00/ 60 * > > > > > > > > > > > > > > > > > >	97 95 150 2 >99 >99 M	77.2% 55.7% HC h/50/ 25 2	97.1% 95.6% THC 300/ 200/30/ 20 *	98.69 96.99 MPD 1,000 300/ 150
Agreement Negative Agreement Total Result Positive Agreement Negative Agreement	250 93.8° 97.5° s 96.1° ACE 5,000 * * * * \$ \$	% % % > > L	91.7' 98.7' 96.1' AMPP 11,000 500/ 300 -99.9' -99.9' MTE 300/	% 91 96 96 96 96 96 96 96 96 96 96 96 96 96	.79 3.79 3.19 9.99 9.99 9.99	B2250 300 200 100 66 > 99	7.0% 7.2% nt w 2O 00/ 00/ 00/ 00/ 0.9% 1.9%	ith C BL 10 >99. >99. MD 1,0	22.3% 11.7% Comply 1.9% .9% .9%	me C: 3: 1 >99 >99	98.39 95.29 rcial OC 00/ 00 00 93.9%	Kit CC 1,5-20 15 30 MC OI 30	9.4% 8.8% 8.8% 00C 00/ 00/ 500 * \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	97 95 150 2 >99 >99 M	77.2% 55.7% HC h/50/ 25 2	97.1% 95.6% THC 300/ 200/30/ 20 * *	98.69 96.99 MPD 1,000 300/ 150 *
Agreement Negative Agreement Total Result Positive Agreement Negative Agreement Total Result	250 93.8° 97.5° s 96.1° ACE 5,000 * * s *	% % % > > L	91.7' 98.7' 96.1' AMP 1,000 500/ 300 -99.9' -99.9' MTE 300/ 200	% 91 96 96 96 96 96 96 96 96 96 96 96 96 96		66 99 Remei B2 50 30 20 10 66 > 999 MM 20 MM 20	7.0% 7.2% nt w 2O 00/ 00/ 00/ 00/ 0.9% 1.9%	6 9 6 9 10 10 10 10 10 10 1	22.3% 11.7% Comply 1.9% .9% .9%	me C: 3: 1 >99 >99	98.39 95.29 rcial OC 00/ 00 00 93.9%	Kit CCC 1,5 20 15	9.4% 8.8% 8.8% 00C 00/ 00/ 500 * \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	97 98 150 2 -99 -99 M4 30	7.2% 5.7% HC 1/50/ 9.9% 9.9% 9.9% QL 000	97.1% 95.6% THC 300/ 200/30/ 20 * *	98.69 96.99 MPD 1,000 300/ 150 *
Agreement Negative Agreement	250 93.8° 97.5° s 96.1° ACE 5,000 * * * * * * * * * * * * * * * * * *	% % % > > > L	91.7' 98.7' 96.1' AMPP 11,000 500 99.9' 99.9' MTE 300 200	% AA	9.99 9.99 9.99 9.99 9.99 9.99 9.99	B2 50 30 20 10 66 > 99 MM 20 7 7 8 8 8 8 8 8 8 9 9 9 9 9 9 9 9 1 9 1 9 1	7.0% 7.2% nt w 2O 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00	6 9 6 9 6 9 1 10 1	11.79 11.79 11.79 19.75 19% 19% 19%	me C: 3: 1 >99 >99	98.39 95.29 rcial OC 000/ 000 93.9%	Kit CC 1,5 20 15 30 20 20 10 >99	9.4% 8.8% 8.8% 00C 00/ 00/ 00/ PI 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00	97 95 150 2 >99 >99 Mr 30	7.2% HC	97.1% 95.6% THC 300/30/200/30/ 20 * MEP 500/ 100	98.69 96.99 1,000 300/ 150 * * LSD 50/20 10
Agreement Negative Agreement Total Result Positive Agreement Negative Agreement Total Result	250 93.8° 97.5° s 96.1° ACE 5,000 * * * * * * * * * * * * * * * * * *	% % % > > > L	91.7' 98.7' 96.1' 96.1' 1,000 5000 300 -99.9' 99.9' MTE 3000 200	% 91 96 96 96 96 96 96 96 96 96 96 96 96 96		B2 See B2 See See	7.0% 7.2% nt w 2O 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00	>99. MD 1,00 500 >99.	.9% .9% .9%	me C: 3: 1 >99 >99	98.3% 95.29 rcial OC 000/ 000 93.9% 93.9% DMA 1000	MCC OI 300 200 100 >999	9.4% 9.8% 8.8%	97 95 150 2 >99 M(3)	7.2% 7.2% HC 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9%	97.1% 95.6% THC 300/ 200/30/ 20 * MEP 500/ 100	98.69 96.99 1,000 300/ 150 * * *
Agreement Negative Agreement Total Result Positive Agreement Negative Agreement Total Result	250 93.8° 97.5° s 96.1° ACE 5,000 * * * * * * * * * * * * * * * * * *	% % % % % % % % % % % % % % % % % % %	91.7' 98.7' 96.1' 96.1' 1,000 5000 300 -99.9' 99.9' MTE 3000 200	% 91 98 98 98 98 99 99 99 99 99 99 99 99 99		6 9 9 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	7.0% 7.2% nt w ZO 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00	Section Sect	.9% .9% .9% .9%	me	98.39 95.29 rcial OC 000/ 000 33.9% DMA 600	MCC OI 300 200 100 >999	9.4% 8.8% 8.8% 0C 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/	97 95 150 2 >99 Md 30 >99 >99 >99	7.2% 7.2% HC 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9%	97.1% 95.6% THC 300/30/20 * * MEP 500/ 100 *	98.69 96.99 MPD 1,000 300/ 150 * * * * LSD 50/20 10
Agreement Negative Agreement Total Result Positive Agreement Negative Agreement Total Result	250 93.8° 97.5° \$ 96.1° ACE 5,000 \$ * * * * * * * * * * * * * * * * * * *	% % % > > > L	91.7' 98.7' 96.1' AMP 1,000 500/ 300 -99.9' 99.9' MTE 300/ 200 -99.9	% 91 % 98 % 98 % A B. 30 2 8 99 99 99 99 99 99 99 99 8 99 8 7 8 99 8 99 8 99 8 99 8 99 8 99 8 99 8 99 8 99 8 99 8 99 8 99 8 99 8 99 8 8 99 8	9.99 ET 000/ 000 9.999 9.999 9.999	B2 50 30 20 110 M 20 M 20 M 20 M 20 M 20 M 20 M	7.0% 7.2% nt w 2O 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00	6 9 9 6 9 9 9 9 9 9 9	.9% .9% .9% .9% .9% .9% .9% .9% .9% .9%	me C 3 1	98.39 95.29 rcial OC 00/ 000 93.9% 33.9% bMA 400	MC OO 300 200 100 >999 PC	9.4% 8.8% 8.8% 0C 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/	97 98 98 150 2 >99 >99 Mr 30 >99 >99 >99 >99	7.2% 7.2% 1.55.7% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9%	97.1% 95.6% THC 300/ 200/30/ 20 MEP 500/ 100	98.69 96.99 MPD 1,000 300/ 150 * * * * * * * * * * * * * * * * * * *
Agreement Negative Agreement Total Result Positive Agreement Negative Agreement Total Result	250 93.8° 97.5° \$ 96.1° \$ \$ 96.1° \$ \$ 7-AC 3000/2000/1000 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	% % % > > > L	91.7' 98.7' 96.1' AMPF1,000 1,000 99.9' 99.9' MTE 300, 200 -99.9 -99.9 TCA	% 91 % 98 % A B B 30 % >99 % >99 % >99 % >99 % >99 A T T T T T T T T T T T T T T T T T T T	9.99 ET 000/ 000 9.999 ML	B2 SC SC SC SC SC SC SC S	7.0% 7.2% nt w 2O 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00	Section Sect	.9% .9% .9% .9% .9% .9% .9% .9% .00	Me	98.39 95.29 rcial OC 000/ 000 3.9% DMA 000	MC OO 300 200 100 >999 PC	9.4% 8.8% 00C 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00	97 98 98 150 2 >99 >99 Mr 30 >99 >99 >99 >99	7.2% 7.2% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9%	97.1% 95.6% THC 300/ 200/30/ 20 * * * MEP 500/ 100 DIA	98.69 96.99 MPD 1,000 300/ 150 * * * * * * * * * * * * * * * * * * *
Agreement Negative Agreement Total Result Positive Agreement Negative Agreement Total Result	250 93.8° 97.5° \$ 96.1° \$ \$ 96.1° \$ \$ 7-AC 3000/2000/1000 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	% % % > > > L	91.7' 98.7' 96.1' AMPF 11,000 300 99.9' 99.9' MTE 300, 200 -99.9 -99.9 TCA 1,000	% 91 % 98 % 98 % 98 % A B 33 2 % >99 % >99 % >99 % >99 0 M 1,(55,3 3 % >99 % >90	1.79 3.79 3.79 6.19 6.19 6.00 00 9.99 ET 000 00 9.99 ML 00/ 00/ 00/	B2 B2 S1 S2 S2 S2 S2 S2 S2 S	7.0% 7.2% nt w ZO 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00	MD 1,00 500 200	12.3% 11.79 11.79 19% 1.9% 1.9% 1.9% 1.9% 1.9%	ME 3 M	98.39 95.29 rcial OC 000/ 000 3.9% 3.9% 4.000	MC OO 300 200 100 >999 PC	9.4% 8.8% 00C 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00	97 98 98 150 2 >99 >99 Mr 30 >99 >99 >99 >99	7.2% 7.2% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9%	97.1% 95.6% THC 300/ 200/30/ 20 * * * DIA 300/	98.69 96.99 MPD 1,000 300/ 150 * * * * LSD 50/20 10 * * * * MDP\ 1,000
Agreement Negative Agreement Total Result Positive Agreement Negative Agreement Total Result	250 93.8° 97.5° \$ 96.1° \$ \$ 96.1° \$ \$ 7-AC 3000/2000/1000 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	% % % > > > L	91.7' 98.7' 96.1' AMPF 1,000 300 99.9' 99.9' MTE 300, 200 -99.9 -99.9 TCA 1,000 500	% 91 % 98 % 98 % 98 % A B 33 2 % >99 % >99 % >99 % >99 0 M 1,(55,3 3 % >99 % >90	9.99 9.99 ET 000/ 000 9.99 ML 00/ 00/	B2 B2 S1 S2 S2 S2 S2 S2 S2 S	7.0% 7.2% mt w 7.00/ 000/ 000/ 000/ 000/ 000/ 000/ 000	Section Sect	.9% .9% .9% .9% .9% .9% .9% .9% .9% .9%	ME 3 M	98.39 95.29 rcial OC 000/ 000 3.9% 3.9% 4.000	MC OO 300 200 100 >999 PC	9.4% 8.8% 00C 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00/ 00	97 98 98 150 2 >99 >99 Mr 30 >99 >99 >99 >99	7.2% 7.2% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9% 1.9%	97.1% 95.6% THC 300/ 200/30/ 20 * * * DIA 300/	98.69 96.99 MPD 1,000 300/ 150 * * * * * MDP\ 1,000 500/

Positive Agreement	>99.9%	*	*	>99	.9%	*		*		*	>99.9%	*	*
Negative	>99.9%	*	*	>99	9%	*		*		*	>99.9%	*	*
Agreement													
Total Results	>99.9%	*	*	>99	.9%	*		*		*	>99.9%	*	*
	OXY	EDDP	FYL	K2-50/	6 1	4004	MD	A ET	<u></u>	CLC	ZOL	ZOP	MCA
	300/	300/	300/	30/25		10	50			400			
	100	100	200/	00/20			00	1,00		150		000,00	
			100/20					500					
			/10					30	0				
Positive	*	*	*	*		*	*	*		*	*	*	*
Agreement											_		
Negative	*	*	*	*		*	*	*		*	*	*	*
Agreement	*	*	*	*	-	*	*	*	_	*	*	*	*
Total Results	*	*	*	*		*	*	*		*	*	*	*
	CFYL	CAF	CAT	TR	0	ALI	5	PGB	ΔRI	P/K3	CNB	TZD	GAE
	500/	1,000	-		-	100		50,000/		0	500	200	2,00
	250	.,000			•		<u>ַ</u>	500		٠	000	200	500
Positive	*	*	*	*		*				*	*	*	*
Agreement		-						_		_	-	_	
Negative	*	*	*	*		*		*		*	*	*	*
Agreement													
Total Results	*	*	*	*		*		*		*	*	*	*
		·				l	1		_	_			
	CAR	MPRE				UR-1		KRA		LD	α-PVP	MES	ZAL
	2,000/ 1,000/	100	1,00	0 50	U	/K4 2	25	300	-	0	2,000/ 1,000/	100/ 300	100
	500										500/	300	
	000										300		
Positive	*	*	*	*		*		*		*	*	*	*
												"	
Agreement													
Negative	*	*	*	*		*		*		*	*	*	*
,	*	*	*	*		*		*		*	*	*	*
Negative Agreement			*	*		*						*	*
Negative Agreement	* CIT	* FKET	* RPD	*		* NNE		* SCOP	M	* TZ	* OZP	* PAP	*
Negative Agreement	*	*	*	*		*		*	M	*	*	*	* HM0
Negative Agreement	* CIT	* FKET	* RPD	*		* NNE		* SCOP	M	* TZ	* OZP	* PAP	* HM0 500 300
Negative Agreement Total Results	* CIT 500	* FKET 1,000	* RPD	*		* NNE		* SCOP 500	M [*]	* TZ 00	* OZP 1,000	* PAP 500	* HM0 500 300
Negative Agreement Total Results	* CIT	* FKET	* RPD	*		* NNE		* SCOP	M [*]	* TZ	* OZP	* PAP	* HM0 500 300
Negative Agreement Total Results Positive Agreement	* CIT 500	* FKET 1,000	* RPD 150	* TAI 1,00		* NNE 1,00		* SCOP 500	M' 50	* TZ 00	* OZP 1,000	* PAP 500	* HM0 500 300 250
Negative Agreement Total Results	* CIT 500	* FKET 1,000	* RPD 150	* TAI 1,00		* NNE 1,00		* SCOP 500	M' 50	* TZ 00	* OZP 1,000	* PAP 500	* HM0 500 300 250
Negative Agreement Total Results Positive Agreement Negative Agreement Total	* CIT 500	* FKET 1,000	* RPD 150	* TAI 1,00		* NNE 1,00		* SCOP 500	M' 50	* TZ 00	* OZP 1,000	* PAP 500	* HM0 500 300 250
Negative Agreement Total Results Positive Agreement Negative Agreement	* CIT 500 * * *	* FKET 1,000 * *	* RPD 150 * *	* TAI 1,00	00	* NNE 1,000	0	* SCOP 500 * *	M' 50	* TZ 00	* OZP 1,000	* PAP 500	* HM/ 500 300 250 *
Negative Agreement Total Results Positive Agreement Negative Agreement Total Results	* CIT 500 * * *	* FKET 1,000 * *	* RPD 150 * *	* TAI 1,00 * * and of Co	00 mmc	* NNE 1,000	0 Il Ki	* SCOP 500 * *	M' 50	* TZ 00	* OZP 1,000	* PAP 500	* HMM 500 300 250 *
Negative Agreement Total Results Positive Agreement Negative Agreement Total Results	* CIT 500 * * on GC/	* FKET 1,000 * * * MS date	RPD 150	* TAI 1,00 * * and of Co	oomn Pre	* NNE 1,000 * * * cisio	0 al Ki	* SCOP 500 * * t.	M' 56	* TZ 000 * *	* OZP 1,000	* PAP 500 * *	* HMM 5000 3000 2250 * *
Positive Agreement Positive Agreement Negative Agreement Total Results *Note: Based	t CIT 5000 * * * * * * * * * * * * * * * * *	* FKET 1,000 * * MS dat ed at the	RPD 150	* TAI 1,00 * ad of Co	omn Pre sing	NNIE 1,000 * * * * nerciaio g three preci	oll Kinne did	* SCOP 500 * t.	M 50	* TZ 000 * * *	OZP 1,000 * * * poduct to eard of co	PAP 500	* HMM 5000 3000 2500 * *

and tested at each site. The results gained ≧75% accuracy in ±25% cut-off level specimen and 100% accuracy in negative and $\pm 50\%$ cut-off level specimen.

Analytical Sensitivity

A drug-free urine pool was spiked with drugs at the listed concentrations. The results are summarized below.

Drug Concentration	A0 5,0	000	AN 1,0	/IP 000		/IP 00		ИР 00		AR 00	B/ 20	AR 00	B2 50		B2	
Cut-off Range	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	26	4	26	4	25	5	27	3	27	3	26	4	27	3	27	3

Cut-off 14 16 15 15 15 15 15 15 15 15 15 15 15 15 15	
	15 15 15 15 15 15 15 15
+25% Cut-off 3 27 3 27 3 27 4 26 4 26 3 27 4 26 3 2	27 3 27 4 26 4 26 3 27 4 26 3 27
+50% Cut-off 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0	30 0 30 0 30 0 30 0 30 0 30 0 30 0 30
+300% Cut-off 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0	30 0 30 0 30 0 30 0 30 0 30 0 30 0 30

Drug	BZ	ZO	BZ	ZO	Вι	JP	ВΙ	JP	C	C	CC	С	CC	C	CC	C	CC	C
Concentration	20	00	10	00	1	0		5	1,5	500	30	00	20	00	18	50	10	00
Cut-off Range	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	27	3	27	3	26	4	26	4	25	5	26	4	26	4	27	3	27	3
Cut-off	16	14	14	16	14	16	14	16	15	15	13	17	14	16	16	14	16	14
+25% Cut-off	3	27	3	27	3	27	3	27	3	27	3	27	3	27	4	26	4	26
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30

Drug Concentration		IC 50	TH 5	IC n	Th	IC 5	M ²		M ⁻	-	MI 1.0	ET 000	MI 50		MI 30		M	ET 00
Cut-off Range	-	+	٠	+	-	+	٠.	+	-	+	-	+	-	+	١.	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	27	3	26	4	27	3	27	3	27	3	27	3	27	3	27	3	27	3
Cut-off	15	15	14	16	15	15	13	17	15	15	16	14	15	15	16	14	15	15
+25% Cut-off	4	26	3	27	4	26	4	26	4	26	3	27	4	26	3	27	4	26
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30

Drug Concentration Cut-off Range		MA 000		MA 00	MC O 30		0	PI D0	O 2,0	PI 000	P(5		P(2	CP 5		PX 00
	-	+	•	+	•	+	1	+	•	+	-	+	•	+	,	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	26	4	25	5	26	4	26	4	27	3	26	4	25	5	26	4
Cut-off	15	15	14	16	15	15	15	15	15	15	15	15	15	15	14	16
+25% Cut-off	5	25	4	26	3	27	3	27	5	25	3	27	3	27	3	27
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30

Drug	TN	ЛL	TN	ИL	TN	ИL	T	ML	K	ΕT	KE	ΞT	K	ΞT	K	ΞT	M	QL
Concentration	10	00	20	00	30	00	5	00	1,0	000	50	00	30	00	10	00	30	00
Cut-off Range	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	27	3	27	3	27	3	26	4	27	3	27	3	26	4	27	3	27	3
Cut-off	15	15	15	15	15	15	14	16	16	14	15	15	15	15	15	15	15	15
+25% Cut-off	4	26	4	26	4	26	3	27	3	27	4	26	4	26	3	27	4	26
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30

Drug Concentration	0	ΧY	0	ΧY	C	TC	C	TC	ED	DP	ED	DP	F,	ΥL	F,	/L
-	10	00	30	00	20	00	10	00	30	00	10	00	2	0	1	0
Cut-off Range	·	+	·	+	•	+	•	+	-	+	•	+	•	+	ı	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	27	3	27	3	27	3	27	3	27	3	26	4	27	3	27	3
Cut-off	15	15	15	15	15	15	14	16	15	15	15	15	14	16	15	15
+25% Cut-off	4	26	4	26	4	26	4	26	4	26	3	27	4	26	3	27
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30

					_				_										,	
Drug		K2		K2		MAN		DA		TG		TG		TG		LO		LO	LS	
Concentration	-	50	+	30	+-	10	5	00	3	00	5	00	_	000	4	00	1:	50	2	0
Cut-off Range	ļ-	+	-	+	_	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	+-	_	_	_		30	0	30	0	30	0	_	0	30	0	30	0	30	0
-50% Cut-off	30	+-	_	_	_	+-	30	0	30	0	30	0	-	0	30	0	30	0	30	0
-25% Cut-off	26	-	_	_	_	_	26	4	25	5	26	4	26	4	26	4	26	4	27	3
Cut-off	15	+-	+-	_	_	+-	+	15	+-	14	_	15	_	15	14	16	14	16	14	16
+25% Cut-off	3	-	_	_		26	_	27	4	26	_	27	_	27	5	25	5	25	3	27
+50% Cut-off	0	30	_	-	_	30	+	30	_	30	_	30	_	30	+-	30	0	30	0	30
+300% Cut-of	0	30	0 0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
			1				1		<u> </u>		1.	00	, [<u> </u>		1		1	
Drug	L	SD	2	ZOL	. 2	ZOL	MI	DM/	A T	HC		IOP OPI	′ N	1EP	N	1EP	MI	DPV	E.	ΓG
Concentration		50		50		25	3	300	2	200	1 '	200	5	00	1	00	1,	000	1,5	500
Cut-off Range	H	+	+	T		+	_	+	+	+	+	4	+-	+	+-	+	+-	+	+-	+
0% Cut-off	30	-	+	-	_	_	+-	-	_	+	30	+	_	_	30	·	30	÷	30	0
-50% Cut-off	30	_	_		_	_	+-	-	_	-	30	-	_	_	30	-	30	_	30	0
	_	_	_		_	_	_	-	_	-	_	-	_	_	_	-	+	_	+	
-25% Cut-off	27	_	_	_	_	_	25	+-	26	+-	_	+	_	_	27	+	26	_	27	3
Cut-off	+	4	_	_	_	_	_	+-	+	+-	_	+	_	+	+	+-	+-	+	15	15
+25% Cut-off	3	_	_		_	+	_	27	_	26	_	20	_	26	_	25	+	27	3	27
+50% Cut-off	0	_	_		_	_	_	30	+	30	_	30	_	30	_	30	+	30	+	30
+300% Cut-of	0	30	0 0	3	0 0	30	0	30	0	30	0	30	0 0	30	0	30	0	30	0	30
	140	D) /		D) /	-	. 1			T. .	_		_	14	_	7.0					
Drug	MD		MD		DI.		DI	- 1	TH		TH		K		ZC		ZC		MC	
Concentration	50	_	30	-	30	-	20	-	30	_	30		2	_	30		_	0	50	
Cut-off Range	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	_	30	_	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	_	29	_	30	_	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	25	5	26	4	27	_	27	-	26	_	26	4	25	5	28	2	27	3	28	2
Cut-off	_	15	14	16		15	_		_		_	16	14	16	17	13	17	13	17	13
+25% Cut-off	_	27	3	27	-	27	_	27	_	26	_	26	3	27	3	27	4	26	3	27
+50% Cut-off	0	30	0	30		30	-+	29	_	30	_	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
			_							_										
Drug		ACL	. 7	-AC		7-A			-YL		CAF		CA			RO		LP	1	PVP
Concentration	3	00	+	200	_	10		5	00	+-	,00	-	15		3	50	1	100	+-	000
Cut-off Range	-	+	+-	-	+	-	+	-	+	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	3	_	_	30	0	30	0	3	_	-	30	0	30	0	30	_	30	0
-50% Cut-off	30	0	3	_	_	30	0	30	0	3	_)	30	0	30	0	30	_	30	0
-25% Cut-off	26	4	2	-	-	27	3	25	5	2	_	4	27	3	27	3	28	_	26	4
Cut-off	14	16	+	-		13	17	14	16	_	_	3	17	13	15	15	_	_	_	15
+25% Cut-off	5	25	_	-		4	26	6	24	_	_	4	4	26	3	27	_	+-	+-	27
+50% Cut-off	0	30	+-	_	_	0	30	0	30	_	_	0	0	30	0	30	_	-	+	30
+300% Cut-off	0	30	C	3	30	0	30	0	30	C) [3	0	0	30	0	30	0	30	0	30
	1			OT	T	CA		CA	TC		_	PΙ	TH		_	٩R	-	٩R	C/	
Drug		YL									1 (000	1 2	0	2.0	000	1,0	000	50	00
Concentration	1	00	3	00	<u> </u>	000	_	00	30			_	-	Ė	_					
Concentration Cut-off Range	-	00	-	00	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
Concentration Cut-off Range 0% Cut-off	- 30	00 + 0	- 30	00 + 0	30	+ 0	- 30	+	- 30	+	30	+	- 30	0	30	0	30	0	30	0
Concentration Cut-off Range 0% Cut-off -50% Cut-off	- 30 30	00 + 0 0	30 30	00 + 0	- 30 30	+ 0 0	- 30 30	+ 0	- 30 30	+ 0 0	- 30 30	+ 0 0	- 30 30	0	- 30 30	0	30 30	0	30 30	0
Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off	30 30 27	00 + 0 0 3	30 30 25	00 + 0 0 5	30 30 25	+ 0 0 5	- 30 30 26	+ 0 0 4	- 30 30 27	+ 0 0	30 30 27	+ 0 0 3	- 30 30 26	0 0 4	30 30 28	0 0 2	30 30 27	0 0 3	30 30 27	0 0 3
Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off	- 30 30	00 + 0 0 3	30 30 25	00 + 0 0 5	30 30 25	+ 0 0 5	- 30 30 26	+ 0	- 30 30 27	+ 0 0	- 30 30	+ 0 0 3	- 30 30 26	0 0 4	30 30 28	0	30 30	0 0 3	30 30	0
Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off +25% Cut-off	30 30 27	00 + 0 0 3	30 30 25 15	00 + 0 0 5	- 30 30 25 15	+ 0 0 5	- 30 30 26 14	+ 0 0 4	- 30 30 27	+ 0 0 3 16 27	30 30 27	+ 0 0 3	30 30 26 14	0 4 16 26	30 30 28 16 3	0 0 2	30 30 27	0 0 3	30 30 27	0 0 3 15 26
Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off	30 30 27 15	00 + 0 0 3 15	30 30 25 15 4	00 + 0 0 5	- 30 30 25 15 4	+ 0 0 5 15	- 30 30 26 14 3	+ 0 0 4 16	- 30 30 27 14	+ 0 0 3 16	30 30 27 14	+ 0 0 3 16	30 30 26 14 4	0 0 4 16	30 30 28 16 3	0 0 2 14	30 30 27 16	0 0 3 14	30 30 27 15	0 0 3 15
Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off +25% Cut-off	30 30 27 15 3	00 + 0 0 3 15 27	30 30 25 15 4	00 + 0 0 5 15	- 30 30 25 15 4 0	+ 0 0 5 15 26	- 30 30 26 14 3	+ 0 0 4 16 27	30 30 27 14 3	+ 0 0 3 16 27	- 30 30 27 14 4	+ 0 0 3 16 26	30 30 26 14 4 0	0 4 16 26	30 30 28 16 3	0 2 14 27	30 30 27 16 4	0 0 3 14 26	30 30 27 15 4	0 0 3 15 26
Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off +25% Cut-off +50% Cut-off	30 30 27 15 3	00 + 0 0 3 15 27	30 30 30 25 15 4	00 + 0 0 5 15 26	- 30 30 25 15 4 0	+ 0 0 5 15 26 30	- 30 30 26 14 3	+ 0 0 4 16 27 30	30 30 27 14 3	+ 0 0 3 16 27 30	- 30 30 27 14 4 0	+ 0 3 16 26	30 30 26 14 4 0	0 4 16 26 30	30 30 28 16 3	0 2 14 27 30	30 30 27 16 4 0	0 0 3 14 26 30	30 30 27 15 4	0 3 15 26 30
Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off	10 - 30 30 27 15 3 0	00 + 0 0 3 15 27 30 30	30 30 30 25 15 4 0	00 + 0 0 5 15 26 30 30	- 30 30 25 15 4 0	+ 0 0 5 15 26 30 30	- 30 30 26 14 3 0	+ 0 0 4 16 27 30 30	- 30 30 27 14 3 0	+ 0 0 3 16 27 30 30	30 30 27 14 4 0	+ 0 0 3 16 26 30 30	- 30 30 26 14 4 0 0	0 4 16 26 30 30	- 30 30 28 16 3 0 0	0 2 14 27 30 30	30 30 27 16 4 0 0	0 0 3 14 26 30 30	30 30 27 15 4 0	0 3 15 26 30 30
Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off +25% Cut-off +300% Cut-off -50% Cut-off -50% Cut-off -50% Cut-off -50% Cut-off -50% Cut-off -50% Cut-off	30 30 27 15 3 0	00 + 0 0 3 15 27 30 30	30 30 30 25 15 4 0	00 + 0 0 5 15 26 30	- 30 30 25 15 4 0	+ 0 0 5 15 26 30 30	30 30 26 14 3 0 0	+ 0 0 0 4 16 27 30 30 P 50	30 30 27 14 3 0 0	+ 0 0 3 16 27 30 30	30 30 27 14 4 0	+ 0 0 3 16 26 30 30	- 30 30 26 14 4 0 0 GAE 2,00	0 4 16 26 30 30	- 30 30 28 16 3 0 0	0 2 14 27 30 30	30 30 27 16 4 0 0	0 0 3 14 26 30 30	30 30 27 15 4 0	0 3 15 26 30
Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off 425% Cut-off +50% Cut-off +300% Cut-off Drug Concentratior Cut-off Range	30 30 27 15 3 0	00 + 0 0 0 3 15 27 30 30 MPI 150	30 30 25 15 4 0 0	00 + 0 0 0 5 15 26 30 30	30 30 25 15 4 0 0	+ 0 0 5 15 26 30 30 1,0	30 30 26 14 3 0 0	+ 0 0 4 16 27 30 30 -	30 30 27 14 3 0 0	+ 0 0 3 16 27 30 30	30 30 27 14 4 0 0	+ 0 0 3 16 26 30 30	30 30 26 14 4 0 0	0 4 16 26 30 30 30 +	30 30 28 16 3 0 0	0 0 2 14 27 30 30	30 30 27 16 4 0 0	0 0 3 14 26 30 30	30 30 27 15 4 0 0	0 3 15 26 30 30
Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentratior Cut-off Range 0% Cut-off	30 30 27 15 3 0 0	00 + 0 0 3 15 27 30 30 MPI 150 0	30 30 30 25 15 4 0 0	00 + 0 0 0 5 15 26 30 30 MF 30 - 30	30 30 25 15 4 0 0	+ 0 0 5 15 26 30 30 MI 1,0	30 30 26 14 3 0 0	+ 0 0 4 16 27 30 30 - 30	30 30 27 14 3 0 0	+ 0 0 3 16 27 30 30 F	30 30 27 14 4 0 0 PGB 500 ++	+ 0 0 3 16 26 30 30	30 30 26 14 4 0 0	0 0 4 16 26 30 30 30	30 30 28 16 3 0 0	0 0 2 14 27 30 30 0 +	30 30 27 16 4 0 0	0 0 3 14 26 30 30 30 + 0	30 30 27 15 4 0 0	0 3 15 26 30 30
Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentratior Cut-off Range 0% Cut-off -50% Cut-off	30 30 27 15 3 0 0	00	30 30 30 25 15 4 0 0	H 0 0 5 15 26 30 30 S S S S S S S S S S S S S S S S S	30 30 25 15 4 0 0 0 + 0	+ 0 0 5 15 26 30 30 MI 1,0 - 30	- 30 30 26 14 3 0 0 0 PD 000 + 0	+ 0 0 4 16 27 30 30 - 30 30	30 30 27 14 3 0 0	+ 0 0 3 16 27 30 30 - 30 30	30 30 27 14 4 0 0 0 PGB 500 ++	+ 0 0 3 16 26 30 30	30 30 26 14 4 0 0 0 GAE 22,000	0 0 4 16 26 30 30 30 ++	30 30 28 16 3 0 0 TZ 20 -	0 0 2 14 27 30 30 0 + 0 0	30 30 27 16 4 0 0 CN 50 - 30 30	0 0 3 14 26 30 30	30 30 27 15 4 0 0 P/ 50 - 30 30	0 0 3 15 26 30 30 30 + +
Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentratior Cut-off Range 0% Cut-off -50% Cut-off	30 30 27 15 3 0 0	00 + 0 0 3 15 27 30 30 15 - 0 0 6	30 30 30 25 15 4 0 0	+ 0 0 5 15 26 30 30 - 30 30 27	30 30 30 25 15 4 0 0 0 + 0 0	+ 0 0 0 5 15 26 30 30 - 30 30 26	- 30 30 26 14 3 0 0 0	+ 0 0 4 16 27 30 30 30 - 30 30 30 25	30 30 27 14 3 0 0 0 GB ,,000 + 0 0 5	+ 0 0 3 16 27 30 30 30 F - 3 30 30 22	30 30 27 14 4 0 0 0 ++0 0 0 0 0	+ 0 0 3 16 26 30 30	30 30 26 14 4 0 0 0 GAE 22,00 -	0 0 4 16 26 30 30 30 ++	- 30 30 28 16 3 0 0 - TZ 20 - 330 330	0 0 2 14 27 30 30 0 + 0 0 2	30 30 27 16 4 0 0 CN 50 - 30 30 27	0 0 3 14 26 30 30 30 + 0 0 3	30 30 27 15 4 0 0 - 30 30 29	0 0 3 15 26 30 30 30 + 0 0
Concentration Cut-off Range 0% Cut-off -50% Cut-off -25% Cut-off +25% Cut-off +50% Cut-off +300% Cut-off Drug Concentratior Cut-off Range 0% Cut-off -50% Cut-off	30 30 27 15 3 0 0	00 + 0 0 3 15 27 30 30 15 - 0 0 6	30 30 30 25 15 4 0 0	H 0 0 5 15 26 30 30 S S S S S S S S S S S S S S S S S	30 30 25 15 4 0 0 0 + 0	+ 0 0 5 15 26 30 30 MI 1,0 - 30	- 30 30 26 14 3 0 0 0 PD 000 + 0	+ 0 0 4 16 27 30 30 - 30 30	30 30 27 14 3 0 0 0 GB,000 + 0	+ 0 0 3 16 27 30 30 30 F - 3 30 30 22	30 30 27 14 4 0 0 0 ++0 0 0 0 0	+ 0 0 3 16 26 30 30	30 30 26 14 4 0 0 0 GAE 22,00 -	0 0 4 16 26 30 30 30 ++	30 30 28 16 3 0 0 TZ 20 -	0 0 2 14 27 30 30 0 + 0 0	30 30 27 16 4 0 0 CN 50 - 30 30	0 0 3 14 26 30 30 30 + 0	30 30 27 15 4 0 0 P/ 50 - 30 30	0 0 3 15 26 30 30 4P 00 + + 0

+25% Cut-off	5	2	5 5	5 2	25	5	25	5	25	6	24	3	2	7	3	27	4	26	1	29
+50% Cut-off	0	30) () 3	30	0	30	0	30	0	30	0	3)	0	30	0	30	0	30
+300% Cut-off	0	30) () 3	30	0	30	0	30	0	30	0	3)	0	30	0	30	0	30
Drug	AE	P/	Q.	TP	FI	_X	K	RA	TL	.D	α-P	VP	α-F	VP	α-F	PVP	L	SD	н	ЛΟ
Concentration	K3	10	1,0	000	50	00	30	00	5	0	2,0	00	50	00	3	00	1	10	50	00
Cut-off Range	-	+	•	+	-	+	-	+	-	+	1	+		+	-	+	-	+	-	+
00/ 0:-1 -#	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
0% Cut-off	5	_	,																	
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0

Drug	AE	BP/	Q	TP	FI	_X	KF	RA	TI	_D	α-P	VP	α-P	VP	α-P	VP	LS	SD	HN	ΛО
Concentration	КЗ	10	1,0	000	50	00	30	00	5	0	2,0	000	50	00	30	00	1	0	50	00
Cut-off Range	-	+	-	+	-	+	-	+	-	+	-	+	ı	+	ı	+	ı	+	ı	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	25	5	29	1	29	1	28	2	29	1	26	4	27	3	27	3	27	3	28	2
Cut-off	15	15	15	15	15	15	14	16	15	15	15	15	15	15	15	15	14	16	15	15
+25% Cut-off	4	26	1	29	2	28	1	29	1	29	3	27	3	27	3	27	3	27	3	27
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30

Drug Concentration	-	OT OO	C(OT 0	C(CF 25	YL 50		/L 00	Z/	AL 00	MP	RD 00		AP 000	C 50	IT 00	FK 1,0	ET	UR- /k 2	
Cut-off Range	-	+	1	+	1	+	ı	+	1	+	ı	+	-	+	-	+	ı	+	ı	+	ı	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	26	4	27	3	27	3	25	5	27	3	27	3	27	3	27	3	27	3	27	3	28	2
Cut-off	14	16	16	14	15	15	14	16	15	15	15	15	15	15	15	15	15	15	15	15	15	15
+25% Cut-off	3	27	4	26	4	26	6	24	3	27	4	26	2	28	4	26	4	26	3	27	3	27
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30

Drug Concentration		PD 50		OP 00		ND 000	l	TZ 00		ZP 000		ES 00		ES 00		YL 00	l	ИО 50	l	00 00	G <i>i</i> 50	ΑB 00
Cut-off Range	-	+	-	+	-	+	-	+	-	+	-	+	1	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	27	3	26	4	27	3	27	3	27	3	27	3	27	3	27	3	28	2	28	2	27	3
Cut-off	15	15	14	16	15	15	15	15	14	16	14	16	14	16	17	13	15	15	15	15	15	15
+25% Cut-off	4	26	3	27	4	26	4	26	4	26	5	25	4	26	4	26	3	27	2	28	3	27
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30

Analytical Specificity

The following table lists the concentrations of compounds (ng/mL) that are detected as positive in urine by the Multi-Drug Rapid Test at 5 minutes.

Analytes	conc. (ng/n	nL) Analytes	conc. (ng/mL)
	ACETAMINOP	HEN (ACE 5,000)	
Acetaminophen	5,000		
	AMPHETAMI	NE (AMP 1,000)	
D,L-Amphetamine sulfate	300	Phentermine	1,000
L-Amphetamine	25,000	Maprotiline	50,000
(±) 3,4-Methylenedioxy	500	Methoxyphenamine	6,000
amphetamine	500	D-Amphetamine	1,000
	AMPHETAM	INE (AMP 500)	
D,L-Amphetamine sulfate	150	Phentermine	500
L-Amphetamine	12,500	Maprotiline	25,000
(±) 3,4-Methylenedioxy	050	Methoxyphenamine	3,000
amphetamine	250	D-Amphetamine	500
	AMPHETAM	INE (AMP 300)	
D,L-Amphetamine sulfate	75	Phentermine	300
L-Amphetamine	10,000	Maprotiline	15,000
(±) 3,4-Methylenedioxy	450	Methoxyphenamine	2,000
amphetamine	150	D-Amphetamine	300
	BARBITURA	TES (BAR 300)	
Amobarbital	5,000	Alphenol	600

5,5-Diphenylhydantoin	8,000	Aprobarbital	500
Allobarbital	600	Butabarbital	200
Barbital	8,000	Butalbital	8,000
Talbutal	200	Butethal	500
Cyclopentobarbital	30,000	Phenobarbital	300
Pentobarbital	8,000	Secobarbital	300
		TES (BAR 200)	
Amobarbital	3,000	Alphenol	400
5,5-Diphenylhydantoin	5,000	Aprobarbital	300
Allobarbital	400	Butabarbital	150
Barbital	5,000	Butalbital	5,000
Talbutal	150	Butethal	300
Cyclopentobarbital	20,000	Phenobarbital	200
			200
Pentobarbital	5,000	Secobarbital	200
		PINES (BZO 500)	1, 500
Alprazolam	200	Bromazepam	1,500
a-hydroxyalprazolam	2,500	Chlordiazepoxide	1,500
Clobazam	300	Nitrazepam	300
Clonazepam	800	Norchlordiazepoxide	200
Clorazepatedipotassium	800	Nordiazepam	1,500
Delorazepam	1,500	Oxazepam	500
Desalkylflurazepam	300	Temazepam	300
Flunitrazepam	300	Diazepam	500
(±) Lorazepam	5,000	Estazolam	10,000
RS-Lorazepamglucuronide	300	Triazolam	5,000
Midazolam	10,000		-,
		PINES (BZO 300)	I
Alprazolam	100	Bromazepam	900
a-hydroxyalprazolam	1,500	Chlordiazepoxide	900
Clobazam	200	Nitrazepam	200
Clonazepam	500	Norchlordiazepoxide	100
Clorazepatedipotassium	500		900
		Nordiazepam	
Delorazepam	900	Oxazepam	300
Desalkylflurazepam	200	Temazepam	100
Flunitrazepam	200	Diazepam	300
(±) Lorazepam	3,000	Estazolam	6,000
RS-Lorazepamglucuronide	200	Triazolam	3,000
Midazolam	6,000		
	BENZODIAZE	PINES (BZO 200)	
Alprazolam	70	Bromazepam	600
a-hydroxyalprazolam	1,000	Chlordiazepoxide	600
Clobazam	120	Nitrazepam	120
Clonazepam	300	Norchlordiazepoxide	70
Clorazepatedipotassium	300	Nordiazepam	600
Delorazepam	600	Oxazepam	200
Desalkylflurazepam	120	Temazepam	70
Flunitrazepam	120	Diazepam	200
	2,000		4,000
(±) Lorazepam		Estazolam	
RS-Lorazepamglucuronide	120	Triazolam	2,000
Midazolam	4,000		
		PINES (BZO 100)	1
Alprazolam	40	Bromazepam	300
a-hydroxyalprazolam	500	Chlordiazepoxide	300
Clobazam	60	Nitrazepam	60
Clonazepam	150	Norchlordiazepoxide	40
Clorazepatedipotassium	150	Nordiazepam	300
Delorazepam	300	Oxazepam	100
Desalkylflurazepam	60	Temazepam	40
Flunitrazepam	60	Diazepam	100
(±) Lorazepam	1,000	Estazolam	2,000
RS-Lorazepamglucuronide	60	Triazolam	1,000
Midazolam	2,000		1

E	UPRENORPHI	NE (BUP 10)	
Buprenorphine	10	Norbuprenorphine	50
Buprenorphine 3-D-Glucuronide	50	Norbuprenorphine	100
		3-D-Glucuronide	100
	BUPRENORPH	· · · · · · · · · · · · · · · · · · ·	hr.
Buprenorphine	5	Norbuprenorphine Norbuprenorphine	25
Buprenorphine 3-D-Glucuronide	25	3-D-Glucuronide	50
	COCAINE (CO		
Benzoylecgonine		Cocaethylene	100,000
Cocaine HCI	1200	Ecgonine	150,000
	COCAINE (C		•
Benzoylecgonine		Cocaethylene	20,000
Cocaine HCI	200	Ecgonine	30,000
	COCAINE (C		
Benzoylecgonine	200	Cocaethylene	13,500
Cocaine HCI	135	Ecgonine	20,000
	COCAINE (C	· · · · · · · · · · · · · · · · · · ·	1
Benzoylecgonine	150	Cocaethylene	1,0000
Cocaine HCI	120	Ecgonine	15,000
Danner danner in s	COCAINE (C		7 000
Benzoylecgonine	100	Cocaethylene	7,000
Cocaine HCI	80 MARIJUANA	Ecgonine (THC 300)	10,000
Cannabinol	200,000	Δ ⁸ -THC	100,000
11-nor-△ ⁸ -THC-9 COOH	200,000	Δ ⁹ -THC	100,000
11-nor-Δ ⁹ -THC-9 COOH	300	Z -111C	100,000
THE A THE SECON	MARIJUANA	(THC 200)	1
Cannabinol		Δ ⁸ -THC	68,000
11-nor-△ ⁸ -THC-9 COOH	120	Δ ⁹ -THC	68,000
11-nor-△ ⁹ -THC-9 COOH	200	-	
	MARIJUANA	(THC 150)	•
Cannabinol		∆ ⁸ -THC	50,000
11-nor-∆ ⁸ -THC-9 COOH	100	∆ ⁹ -THC	50,000
11-nor-∆ ⁹ -THC-9 COOH	150		
	MARIJUANA		
Cannabinol	35,000	Δ ⁸ -THC	17,000
11-nor- Δ^8 -THC-9 COOH	30	∆ ⁹ -THC	17,000
11-nor-△ ⁹ -THC-9 COOH	50		
	MARIJUANA		1
Cannabinol	20,000	Δ ⁸ -THC Δ ⁹ -THC	10,000
11-nor-△ ⁸ -THC-9 COOH 11-nor-△ ⁹ -THC-9 COOH	20	A-THC	10,000
11-1101-7 -1 LC-A COOH	30 MARIJUANA	(THC 25)	1
Cannabinol	17,500	Δ ⁸ -THC	8,500
11-nor-△ ⁸ -THC-9 COOH	15	Δ ⁹ -THC	8,500
11-nor-Δ ⁹ -THC-9 COOH	25		-,000
,	MARIJUANA	(THC 20)	
Cannabinol	14,000	△ ⁸ -THC	6,800
11-nor-△ ⁸ -THC-9 COOH	12	Δ ⁹ -THC	6,800
11-nor-△ ⁹ -THC-9 COOH	20		
	METHADONE	(MTD 300)	
Methadone	300	Doxylamine	100,000
	METHADONE	·	
Methadone	200	Doxylamine	65,000
	1	NE (MET 1, 000)	1
ρ-Hydroxymethamphetamine	25,000	(±)-3,4-Methylenedioxy-	12,500
D-Methamphetamine	1,000	methamphetamine	
L-Methamphetamine	20,000	Mephentermine	50,000
	THAMPHETAM		1
ρ-Hydroxymethamphetamine	12,500	(±)-3,4-Methylenedioxy-	6,250
D-Methamphetamine	500	methamphetamine	1

L-Methamphetamine	10,000	Mephentermine	25,000
	THAMPHETAM	• • • • • • • • • • • • • • • • • • • •	_0,000
p-Hydroxymethamphetamine	7,500	(±)-3,4-Methylenedioxy-	
D-Methamphetamine	300	methamphetamine	3,750
L-Methamphetamine	6,000	Mephentermine	15,000
ME	THAMPHETAM		•
ρ-Hydroxymethamphetamine	5,000	(±)-3,4-Methylenedioxy-	0.500
D-Methamphetamine	200	methamphetamine	2,500
L-Methamphetamine	4,000	Mephentermine	10,000
METHYLENEDIOXY	METHAMPHET	AMINE (MDMA 1, 000) Ecst	asy
(±) 3,4-Methylenedioxy-	1,000	3,4-Methylenedioxyethyl-	600
methamphetamine HCI	1,000	amphetamine	000
(±) 3,4-Methylenedioxyampheta	6,000		
mine HCI			
	YMETHAMPHE	TAMINE (MDMA 500) Ecsta	sy
(±) 3,4-Methylenedioxy-	500	3,4-Methylenedioxyethyl-	300
methamphetamine HCI		amphetamine	
(±) 3,4-Methylenedioxyampheta	3,000		
mine HCI	I VMETH AMDUE	 TAMINE (MDMA 300) Ecsta	EV.
(±) 3,4-Methylenedioxy-		3,4-Methylenedioxyethyl-	
methamphetamine HCI	300	amphetamine	180
(±) 3,4-Methylenedioxyampheta	<u> </u>	ampriotatiino	
mine HCI	1,800		
	MORPHINE (MO	OP/OPI 300)	1
Codeine	200	Norcodeine	6,000
Levorphanol	1,500	Normorphone	50,000
Morphine-3-β-D-Glucuronide	800	Oxycodone	30,000
Ethylmorphine	6,000	Oxymorphone	50,000
Hydrocodone	50,000	Procaine	15,000
Hydromorphone	3,000	Thebaine	6,000
6-Monoacethylmorphine	300	Morphine	300
,	MORPHINE (MO	OP/OPI 200)	
Codeine	160	Norcodeine	4,000
Levorphanol	1,000	Normorphone	40,000
Morphine-3-β-D-Glucuronide	600	Oxycodone	20,000
Ethylmorphine	4,000	Oxymorphone	40,000
Hydrocodone	40,000	Procaine	10,000
Hydromorphone	2,000	Thebaine	4,000
6-Monoacethylmorphine	200	Morphine	200
	MORPHINE (MO	· · · · · · · · · · · · · · · · · · ·	1
Codeine	80	Norcodeine	2,000
Levorphanol	500	Normorphone	20,000
Morphine-3-β-D-Glucuronide	300	Oxycodone	10,000
Ethylmorphine	2,000	Oxymorphone	20,000
Hydrocodone	20,000	Procaine	5,000
Hydromorphone S. Managasathulmarnhina	1,000	Thebaine	2,000
6-Monoacethylmorphine	200	Morphine	100
	ETHAQUALON	IE (IVIQL 300)	
Methaqualone	300	<u> </u>	l .
Codeine	RPHINE/OPIA		2 000
Ethylmorphine	2,000	Morphine	2,000
Ethylmorphine	2,000 3,000	Morphine Norcodeine	25,000
Hydrocodone	2,000 3,000 50,000	Morphine Norcodeine Normorphone	25,000 50,000
Hydrocodone Hydromorphone	2,000 3,000 50,000 15,000	Morphine Norcodeine Normorphone Oxycodone	25,000 50,000 25,000
Hydrocodone Hydromorphone Levorphanol	2,000 3,000 50,000 15,000 25,000	Morphine Norcodeine Normorphone Oxycodone Oxymorphone	25,000 50,000 25,000 25,000
Hydrocodone Hydromorphone Levorphanol 6-Monoacetylmorphine	2,000 3,000 50,000 15,000 25,000 3,000	Morphine Norcodeine Normorphone Oxycodone Oxymorphone Procaine	25,000 50,000 25,000 25,000 50,000
Hydrocodone Hydromorphone Levorphanol 6-Monoacetylmorphine Morphine 3-β-D-glucuronide	2,000 3,000 50,000 15,000 25,000 3,000 2,000	Morphine Norcodeine Normorphone Oxycodone Oxymorphone Procaine Thebaine	25,000 50,000 25,000 25,000
Hydrocodone Hydromorphone Levorphanol 6-Monoacetylmorphine Morphine 3-β-D-glucuronide	2,000 3,000 50,000 15,000 25,000 3,000 2,000 RPHINE/OPIA	Morphine Norcodeine Normorphone Oxycodone Oxymorphone Procaine Thebaine TE (OPI 1,000)	25,000 50,000 25,000 25,000 50,000 25,000
Hydrocodone Hydromorphone Levorphanol 6-Monoacetylmorphine Morphine 3-β-D-glucuronide MC	2,000 3,000 50,000 15,000 25,000 3,000 2,000 PRPHINE/OPIA	Morphine Norcodeine Normorphone Oxycodone Oxymorphone Procaine Thebaine IE (OPI 1,000) Morphine	25,000 50,000 25,000 25,000 50,000 25,000
Hydrocodone Hydromorphone Levorphanol 6-Monoacetylmorphine Morphine 3-β-D-glucuronide	2,000 3,000 50,000 15,000 25,000 3,000 2,000 RPHINE/OPIA	Morphine Norcodeine Normorphone Oxycodone Oxymorphone Procaine Thebaine TE (OPI 1,000)	25,000 50,000 25,000 25,000 50,000 25,000

Levorphanol	12,500	Oxymorphone	12,500
6-Monoacetylmorphine	1,500	Procaine	25,000
Morphine 3-β-D-glucuronide	1,000	Thebaine	12,500
	MEPERIDIN	E (MPRD 100)	
Normeperidine	100	Meperidine	100
	PHENCYCL	DINE (PCP 50)	
Phencyclidine	50	4-Hydroxyphencyclidine	25,000
	PHENCYCL	DINE (PCP 25)	
Phencyclidine	25	4-Hydroxyphencyclidine	12,500
		IENE (PPX 300)	
D-Propoxyphene	300	D-Norpropoxyphene	300
		RESSANTS (TCA 1,000)	
Nortriptyline	1,000	Imipramine	400
Nordoxepine	500	Clomipramine	50,000
Trimipramine	3,000	Doxepine	2,000
Amitriptyline	1,500	Maprotiline	2,000
Promazine	3,000	Promethazine	50,000
Desipramine	200	Perphenazine	50,000
Cyclobenzaprine	2,000	Dithiaden	10,000
		PRESSANTS (TCA 500)	
Nortriptyline	500	Imipramine	200
Nordoxepine	250	Clomipramine	25,000
Trimipramine	1,500	Doxepine	1,000
Amitriptyline	750	Maprotiline	1,000
Promazine	1,500	Promethazine	25,000
Desipramine	100	Perphenazine	25,000
Cyclobenzaprine	1,000	Dithiaden	5,000
		PRESSANTS (TCA 300)	1.00
Nortriptyline	300	Imipramine	120
Nordoxepine	150	Clomipramine	15,000
Frimipramine	900	Doxepine	600
Amitriptyline	450	Maprotiline	600
Promazine	900	Promethazine	15,000
Desipramine	60	Perphenazine	15,000
Cyclobenzaprine	600 TD AM A D (Dithiaden	3,000
Doomothyl sig tramadal	200	DL (TML 100)	10.000
n-Desmethyl-cis-tramadol Cis-tramadol	100	o-Desmethyl-cis-tramadol Phencyclidine	10,000
Procyclidine	100,000	d,I-O-Desmethyl venlafaxine	100,000 50,000
rocyclidine		DL (TML 200)	50,000
n-Desmethyl-cis-tramadol	400	o-Desmethyl-cis-tramadol	20,000
Cis-tramadol	200	Phencyclidine	200,000
Procyclidine	200,000	d,I-O-Desmethyl venlafaxine	100,000
Tocyclianie		DL (TML 300)	100,000
n-Desmethyl-cis-tramadol	600	o-Desmethyl-cis-tramadol	30,000
Cis-tramadol	300	Phencyclidine	300,000
Procyclidine	300,000	d,I-O-Desmethyl venlafaxine	150,000
		DL (TML 500)	.00,000
n-Desmethyl-cis-tramadol	10,00	o-Desmethyl-cis-tramadol	50,000
Cis-tramadol	500	Phencyclidine	500,000
Procyclidine	500,000	d,I-O-Desmethyl venlafaxine	250,000
rocycliane		<u> </u>	230,000
		(KFT 1 000)	
(etamine	KETAMINE	(KET 1, 000)	25 000
	1,000	Benzphetamine	25,000 25,000
Dextromethorphan	1,000 2,000	Benzphetamine (+) Chlorpheniramine	25,000
Dextromethorphan Methoxyphenamine	1,000 2,000 25,000	Benzphetamine (+) Chlorpheniramine Clonidine	25,000 100,000
Dextromethorphan Methoxyphenamine J-Norpropoxyphene	1,000 2,000 25,000 25,000	Benzphetamine (+) Chlorpheniramine Clonidine EDDP	25,000 100,000 50,000
Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine	1,000 2,000 25,000 25,000 25,000	Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine	25,000 100,000 50,000 50,000
Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine	KETAMINE 1,000 2,000 25,000 25,000 25,000 25,000	Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol	25,000 100,000 50,000 50,000 50,000
Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine Pentazocine	KETAMINE 1,000 2,000 25,000 25,000 25,000 25,000 25,000 25,000	Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol MDE	25,000 100,000 50,000 50,000 50,000 50,000
Ketamine Dextromethorphan Methoxyphenamine d-Norpropoxyphene Promazine Promethazine Pentazocine Phencyclidine Tetrahydrozoline	KETAMINE 1,000 2,000 25,000 25,000 25,000 25,000	Benzphetamine (+) Chlorpheniramine Clonidine EDDP 4-Hydroxyphencyclidine Levorphanol	25,000 100,000 50,000 50,000 50,000

(1R, 2S) - (-)-Ephedrine	100,000	3,4-Methylendioxymetham-	100,000
Disopyramide	25,000	phetamine (MDMA) Thioridazine	50.000
Disopyramide		E (KET 500)	50,000
Ketamine	500	Benzphetamine	12,500
Dextromethorphan	1,000	(+) Chlorpheniramine	12,500
Methoxyphenamine	12.500	Clonidine	50,000
d-Norpropoxyphene	12,500	EDDP	25,000
Promazine	12,500	4-Hydroxyphencyclidine	25,000
Promethazine	12,500	Levorphanol	25,000
Pentazocine	12,500	MDE	25,000
Phencyclidine	12,500	Meperidine	12,500
Tetrahydrozoline	250	d-Methamphetamine	25,000
Mephentermine	12,500	I-Methamphetamine	25,000
(1R, 2S) - (-)-Ephedrine	50,000	3,4-Methylendioxymetham- phetamine (MDMA)	50,000
Disopyramide	12,500	Thioridazine	25,000
1,	KETAMIN	E (KET 300)	•
Ketamine	300	Benzphetamine	6,250
Dextromethorphan	600	(+) Chlorpheniramine	6,250
Methoxyphenamine	6,250	Clonidine	30,000
d-Norpropoxyphene	6,250	EDDP	15,000
Promazine	6,250	4-Hydroxyphencyclidine	15,000
Promethazine	6,250	Levorphanol	15,000
Pentazocine	6,250	MDE	15,000
Phencyclidine	6,250	Meperidine	6,250
Tetrahydrozoline	150	d-Methamphetamine	15,000
Mephentermine	6,250	I-Methamphetamine	15,000
1R, 2S) - (-)-Ephedrine	30,000	3,4-Methylendioxymetham- phetamine (MDMA)	30,000
Disopyramide	6,250	Thioridazine	15,000
.,,	KETAMIN	E (KET 100)	
Ketamine	100	Benzphetamine	2,000
Dextromethorphan	200	(+) Chlorpheniramine	2,000
Methoxyphenamine	2,000	Clonidine	10,000
d-Norpropoxyphene	2,000	EDDP	5,000
Promazine	2,000	4-Hydroxyphencyclidine	5,000
Promethazine	2,000	Levorphanol	5,000
Pentazocine	2,000	MDE	5,000
Phencyclidine	2,000	Meperidine	2,000
Tetrahydrozoline	50	d-Methamphetamine	5,000
Mephentermine	2,000	I-Methamphetamine	5,000
(1R, 2S) - (-)-Ephedrine	10,000	Thioridazine	5,000
Disopyramide	2,000	3,4-Methylendioxymetham- phetamine (MDMA)	10,000
	OXYCODO	NE (OXY 300)	
Oxycodone	300	Hydromorphone	150,000
Oxymorphone	900	Naloxone	75,000
_evorphanol	15,000	Naltrexone	75,000
Hydrocodone	75,000		
	OXYCODO	NE (OXY 100)	
Oxycodone	100	Hydromorphone	50,000
Oxymorphone	300	Naloxone	25,000
_evorphanol	50,000	Naltrexone	25,000
Hydrocodone	25,000		
		(COT 300)	1
-)-Cotinine	300 COTININE	(-)-Nicotine E (COT 200)	7,500
-)-Cotinine	200	(-)-Nicotine	5,000
	COTININE	(COT 100)	
(-)-Cotinine	100	(-)-Nicotine	2,500

500	(-)-Nicotine	12,500
	<u> </u>	1,250
		1,250
	<u> </u>	250
		300
	` '	
	•	100
		100
	`	80,000
		300
-		150,000
	•	100,000
	1	30,000
		200
		100,000
	•	100,000
	` '	15,000
		100
	-	50,000
	•	00,000
	1	15,000
	· ·	100
		50,000
	·	5,000
		0,000
	1	8,000
	· ·	50
		25,000
	· · · · · · · · · · · · · · · · · · ·	2,500
		2,000
	` '	50
		500
	этт ото отгушемуренку.	
	RLIIIANA (K2-30)	_
		30
		300
	SVIII 010 0 TIYGIOXYPEIRYI	
	RLIIIANA (K2-25)	_
		25
		250
	2.TTT 010 0 TIYUTOXYPOTILYI	200
	DRPHINE (6-MAM 10)	
	` '	100,000
		. 55,550
		6,000
500		2,000
300		1,000
		50,000
	•	50,000
		30,000
	- · · · ·	60,000
	cınanoı	>100,000
	IDONIDE (ETC 500)	
ITE-p-D-GLUCC		50,000
E00		
500	Propyl β-D-glucuronide	
100,000	Morphine 6β-glucuronide	100,000
100,000 100,000		100,000
100,000 100,000 >100,000	Morphine 6β-glucuronide Ethanol	100,000
100,000 100,000 >100,000	Morphine 6β-glucuronide	
	COTININE 50	COTININE (COT 50) 50

Morphine 3β-glucuronide	>100,000	Morphine 6β-glucuronide	>100,000
Glucuronic Acid	>100,000	Ethanol	>100,000
Methanol	>100,000		
ETHYL	-β-D-GLUCURO	ONIDE (ETG 1,500)	
Ethyl- β -D-Glucuronide	1,500	Propyl β-D-glucuronide	150,000
Morphine 3β-glucuronide	>100,000	Morphine 6β-glucuronide	>100,000
Glucuronic Acid	>100,000	Ethanol	>100,000
Methanol	>100,000		
	CLONAZEPAM	(CLO 400)	
Clonazepam	400	Flunitrazepam	300
Alprazolam	200	(±) Lorazepam	1,250
a-hydroxyalprazolam	2,000	RS-Lorazepamglucuronide	250
Bromazepam	1,000	Midazolam	5,000
Chlordiazepoxide	1,000	Nitrazepam	200
Clobazam	250	Norchlordiazepoxide	200
Clorazepatedipotassium	600	Nordiazepam	1,000
Delorazepam	1,000	Oxazepam	350
Desalkylflurazepam	250	Temazepam	150
Diazepam	300	Triazolam	5,000
Estazolam	1,250		
	CLONAZEPAM	(CLO 150)	•
Clonazepam	150	Flunitrazepam	120
Alprazolam	75	(±) Lorazepam	500
a-hydroxyalprazolam	750	RS-Lorazepamglucuronide	100
Bromazepam	400	Midazolam	2,000
Chlordiazepoxide	400	Nitrazepam	75
Clobazam	100	Norchlordiazepoxide	75
Clorazepatedipotassium	250	Nordiazepam	400
Delorazepam	400	Oxazepam	130
Desalkylflurazepam	100	Temazepam	60
Diazepam	120	Triazolam	2,000
Estazolam	500	mazoiam	2,000
	1	IYLAMIDE (LSD 10)	ı
Lysergic Acid Diethylamide	10		
		IYLAMIDE (LSD 20)	ı
Lysergic Acid Diethylamide	20		
		IYLAMIDE (LSD 50)	ı
Lysergic Acid Diethylamide	50		
	THYLPHENIDA	TF (MPD 300)	L
Methylphenidate (Ritalin)	300	Ritalinic Acid	1,000
	THYLPHENIDA		1,000
Methylphenidate (Ritalin)	150	Ritalinic Acid	500
	THYLPHENIDAT		500
Methylphenidate (Ritalin)	350	Ritalinic Aicd	1,000
wetryphenidate (Kitalin)	ZOLPIDEM (1,000
Zolnidom	50	ZOL 30)	
Zolpidem		(701.25)	
- · · ·	ZOLPIDEM (ZOL 23)	1
Zolpidem	25	(MED 500)	
	MEPHEDRONE		L
Mephedrone HCI		R(+)-Methcathinone HCI	7,500
S(-)-Methcathinone HCI	2,500	3-Fluoromethcathinone HCI	7,500
4-Fluoromethcathinone HCI	1,500	Methoxyphenamine	100,000
	MEPHEDRONE		T
Mephedrone HCI	100	R(+)-Methcathinone HCI	1,500
S(-)-Methcathinone HCI	500	3-Fluoromethcathinone HCI	1,500
4-Fluoromethcathinone HCl	300	Methoxyphenamine	100,000
		VALERONE (MDPV 1,000)	1
3, 4-methylenedioxypyrovalerone	•		
		OVALERONE (MDPV 500)	
3, 4-methylenedioxypyrovalerone			<u> </u>
		OVALERONE (MDPV 300)	
3, 4-methylenedioxypyrovalerone	300		1

	DIAZEPAM (DIA 300)	
Diazepam	300	Midazolam	6,000
Clobazam	200	Nitrazepam	200
Clonazepam	500	Norchlordiazepoxide	100
Clorazepate dipotassium	500	Nordiazepam	900
Alprazolam	100	Flunitrazepam	200
a-hydroxyalprazolam	1,500	(±) Lorazepam	3,000
Bromazepam	900	RS-Lorazepam glucuronide	200
Chlordiazepoxide	900	Triazolam	3,000
Estazolam	6,000	Temazepam	100
Delorazepam	900	Oxazepam	300
Desalkylflurazepam	200	D14 000)	
D:	DIAZEPAM (,	Loop
Diazepam	200	Midazolam	4,000
Clobazam	120	Nitrazepam	120
Clorazepam	300	Norchlordiazepoxide	70
Clorazepate dipotassium	300 70	Nordiazepam Flunitrazepam	600 120
Alprazolam		(±) Lorazepam	2,000
a-hydroxyalprazolam Bromazepam	1,000 600	RS-Lorazepam glucuronide	120
Chlordiazepani Chlordiazepoxide	600	Triazolam	2,000
Estazolam	4,000	Temazepam	70
Delorazepam	600	Oxazepam	200
Desalkylflurazepam	120	олагоран.	
	ZOPICLONE (ZOP 300)	1
Zopiclone-x-oxide		Zopiclone	300
	ZOPICLONE		•
Zopiclone-x-oxide	50	Zopiclone	50
ME	THCATHINON	E (MCAT 500)	•
S(-)-Methcathinone HCl	500	R(+)-Methcathinone HCI	1,500
Methoxyphenamine	100,000	3-Fluoromethcathinone HCl	1,500
7-AM	INOCLONAZEF	PAM (7-ACL 300)	
a-hydroxyalprazolam	6,000	Flunitrazepam	3,000
Bromazepam	6,000	RS-Lorazepam glucuronide	2,700
Chlordiazepoxide	6,000	Norchlordiazepoxide	4,500
Clobazam	9,000	Nordiazepam	15,000
Clobazam Clonazepam	9,000 2,400	Temazepam	15,000 9,000
Clonazepam Delorazepam			<u> </u>
Clonazepam Delorazepam Desalkylflurazepam	2,400 6,000 6,000	Temazepam 7-Aminoclonazepam	9,000
Clonazepam Delorazepam Desalkylflurazepam 7-AM	2,400 6,000 6,000 NOCLONAZEF	Temazepam 7-Aminoclonazepam PAM (7-ACL 200)	9,000
Clonazepam Delorazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam	2,400 6,000 6,000 NOCLONAZEF 4,000	Temazepam 7-Aminoclonazepam AM (7-ACL 200) Flunitrazepam	9,000 300 2,000
Clonazepam Delorazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam	2,400 6,000 6,000 NOCLONAZEF 4,000 4,000	Temazepam 7-Aminoclonazepam AM (7-ACL 200) Flunitrazepam RS-Lorazepam glucuronide	9,000 300 2,000 1,800
Clonazepam Delorazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide	2,400 6,000 6,000 NOCLONAZEF 4,000 4,000	Temazepam 7-Aminoclonazepam PAM (7-ACL 200) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide	9,000 300 2,000 1,800 3,000
Clonazepam Delorazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam	2,400 6,000 6,000 NOCLONAZEF 4,000 4,000 4,000 6,000	Temazepam 7-Aminoclonazepam PAM (7-ACL 200) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam	9,000 300 2,000 1,800 3,000 10,000
Clonazepam Delorazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam	2,400 6,000 6,000 NOCLONAZEF 4,000 4,000 4,000 6,000 1,600	Temazepam 7-Aminoclonazepam AM (7-ACL 200) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam Temazepam	9,000 300 2,000 1,800 3,000 10,000 6,000
Clonazepam Delorazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam	2,400 6,000 6,000 NOCLONAZEF 4,000 4,000 6,000 1,600 4,000	Temazepam 7-Aminoclonazepam PAM (7-ACL 200) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam	9,000 300 2,000 1,800 3,000 10,000
Clonazepam Delorazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Desalkylflurazepam	2,400 6,000 6,000 NOCLONAZEF 4,000 4,000 6,000 1,600 4,000 4,000	Temazepam 7-Aminoclonazepam 7-AM (7-ACL 200) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam Temazepam 7-Aminoclonazepam	9,000 300 2,000 1,800 3,000 10,000 6,000
Clonazepam Delorazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Desalkylflurazepam	2,400 6,000 6,000 NOCLONAZEF 4,000 4,000 6,000 1,600 4,000 4,000 4,000 NOCLONAZEF	Temazepam 7-Aminoclonazepam 7-AM (7-ACL 200) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam Temazepam 7-Aminoclonazepam	9,000 300 2,000 1,800 3,000 10,000 6,000
Clonazepam Delorazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Desalkylflurazepam 2-AM a-hydroxyalprazolam	2,400 6,000 6,000 NOCLONAZEF 4,000 4,000 4,000 1,600 4,000 4,000 4,000 NOCLONAZEF 2,000	Temazepam 7-Aminoclonazepam 7-AM (7-ACL 200) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam Temazepam 7-Aminoclonazepam PAM (7-ACL 100) Flunitrazepam	9,000 300 2,000 1,800 3,000 10,000 6,000 200
Clonazepam Delorazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Desalkylflurazepam Desalkylflurazepam a-hydroxyalprazolam Bromazepam Bromazepam	2,400 6,000 6,000 NOCLONAZEF 4,000 4,000 6,000 1,600 4,000 4,000 NOCLONAZEF 2,000	Temazepam 7-Aminoclonazepam 7-AM (7-ACL 200) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepam Nordiazepam T-emazepam 7-Aminoclonazepam Flunitrazepam RS-Lorazepam glucuronide	9,000 300 1,800 3,000 10,000 6,000 200 1,000
Clonazepam Delorazepam Desalkylflurazepam	2,400 6,000 6,000 NOCLONAZEF 4,000 4,000 6,000 1,600 4,000 4,000 4,000 NOCLONAZEF 2,000 2,000	Temazepam 7-Aminoclonazepam 7-Aminoclonazepam Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam Temazepam 7-Aminoclonazepam Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepam	9,000 300 1,800 3,000 10,000 6,000 200 1,000 900 1,500
Clonazepam Delorazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Desalkylflurazepam Desalkylflurazepam T-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam	2,400 6,000 6,000 NOCLONAZEF 4,000 4,000 6,000 1,600 4,000 4,000 4,000 VOCLONAZEF 2,000 2,000 2,000 3,000	Temazepam 7-Aminoclonazepam 7-Aminoclonazepam Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepaxide Nordiazepam Temazepam 7-Aminoclonazepam Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepam glucuronide Norchlordiazepoxide Nordiazepam	9,000 300 2,000 1,800 3,000 10,000 6,000 200 1,000 900 1,500 5,000
Clonazepam Delorazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam	2,400 6,000 6,000 NOCLONAZEF 4,000 4,000 4,000 1,600 4,000 NOCLONAZEF 2,000 2,000 2,000 3,000 800	Temazepam 7-Aminoclonazepam 7-Aminoclonazepam Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam 7-Aminoclonazepam Plunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Norchlordiazepoxide Norchlordiazepoxide Nordiazepam Temazepam	9,000 300 2,000 1,800 3,000 10,000 6,000 200 1,000 900 1,500 5,000 3,000
Clonazepam Delorazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Desalkylflurazepam 7-AM Clordiazepoxide Clobazam Clonazepam Clonazepam	2,400 6,000 6,000 NOCLONAZEF 4,000 4,000 6,000 1,600 4,000 4,000 MOCLONAZEF 2,000 2,000 2,000 800 2,000	Temazepam 7-Aminoclonazepam 7-Aminoclonazepam Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepaxide Nordiazepam Temazepam 7-Aminoclonazepam Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepam glucuronide Norchlordiazepoxide Nordiazepam	9,000 300 2,000 1,800 3,000 10,000 6,000 200 1,000 900 1,500 5,000
Clonazepam Delorazepam Desalkylflurazepam	2,400 6,000 6,000 MOCLONAZEF 4,000 4,000 1,600 1,600 4,000 MOCLONAZEF 2,000 2,000 2,000 800 2,000 2,000 2,000	Temazepam 7-Aminoclonazepam 7-Aminoclonazepam Flunitrazepam RS-Lorazepam glucuronide Nordhordiazepoxide Nordiazepam Temazepam 7-Aminoclonazepam Plunitrazepam RS-Lorazepam glucuronide Norchlordiazepam RS-Lorazepam glucuronide Norchlordiazepam Temazepam Temazepam Temazepam 7-Aminoclonazepam	9,000 300 2,000 1,800 3,000 10,000 6,000 200 1,000 900 1,500 5,000 3,000
Clonazepam Delorazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Desalkylflurazepam Chlordiazepoxide Clobazam Clonazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Delorazepam Desalkylflurazepam	2,400 6,000 6,000 NOCLONAZEF 4,000 4,000 6,000 1,600 4,000 4,000 MOCLONAZEF 2,000 2,000 2,000 800 2,000	Temazepam 7-Aminoclonazepam 7-Aminoclonazepam Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam Temazepam 7-Aminoclonazepam RS-Lorazepam glucuronide Norchlordiazepam RS-Lorazepam glucuronide Norchlordiazepam Temazepam Temazepam Temazepam Temazepam Temazepam Temazepam Temazepam	9,000 300 2,000 1,800 3,000 10,000 6,000 200 1,000 900 1,500 5,000 3,000
Clonazepam Delorazepam Desalkylflurazepam	2,400 6,000 6,000 NOCLONAZEF 4,000 4,000 4,000 1,600 4,000 0,000 1,000 2,000	Temazepam 7-Aminoclonazepam 7-Aminoclonazepam Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam Temazepam 7-Aminoclonazepam PM (7-ACL 100) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepam Nordiazepam Temazepam Temazepam 7-Aminoclonazepam Temazepam 7-Aminoclonazepam	9,000 300 1,800 3,000 10,000 6,000 200 1,000 900 1,500 5,000 3,000 100
Clonazepam Delorazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Desalkylflurazepam Chlordiazepoxide Clobazam Chlordiazepoxide Clobazam Clonazepam Desalkylflurazepam Conazepam Conazepam Conazepam Conazepam Desalkylflurazepam Carfentanyl Sufentanil	2,400 6,000 6,000 NOCLONAZEF 4,000 4,000 4,000 1,600 4,000 1,600 0,000 1,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 ARFENTANYL 500 50,000	Temazepam 7-Aminoclonazepam 7-Aminoclonazepam Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam Temazepam 7-Aminoclonazepam RS-Lorazepam glucuronide Norchlordiazepam RS-Lorazepam glucuronide Norchlordiazepam Temazepam Temazepam Temazepam Temazepam Temazepam Temazepam Temazepam	9,000 300 1,800 1,800 10,000 6,000 200 1,000 900 1,500 5,000 3,000
Clonazepam Delorazepam Desalkylflurazepam	2,400 6,000 6,000 MOCLONAZEF 4,000 4,000 4,000 1,600 4,000 2,000	Temazepam 7-Aminoclonazepam 7-Aminoclonazepam R-Aminoclonazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam 7-Aminoclonazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam Temazepam 7-Aminoclonazepam Temazepam 7-Aminoclonazepam (CFYL 500) Fentanyl Ramifentanil Butyl fentanyl	9,000 300 1,800 1,800 3,000 10,000 6,000 200 1,000 900 1,500 5,000 3,000 100
Clonazepam Delorazepam Desalkylflurazepam 7-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Desalkylflurazepam Desalkylflurazepam T-AM a-hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Chlordiazepoxide Clobazam Chlordiazepaxide Clobazam Clonazepam Desalkylflurazepam Ccarfentanyl Sufentanil (±)cis-3-Menthylfentanyl	2,400 6,000 6,000 NOCLONAZEF 4,000 4,000 4,000 1,600 4,000 1,600 0,000 1,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 ARFENTANYL 500 50,000	Temazepam 7-Aminoclonazepam 7-Aminoclonazepam R-Aminoclonazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam 7-Aminoclonazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam Temazepam 7-Aminoclonazepam Temazepam 7-Aminoclonazepam (CFYL 500) Fentanyl Ramifentanil Butyl fentanyl	9,000 300 1,800 1,800 3,000 10,000 6,000 200 1,000 900 1,500 5,000 3,000 100
Clonazepam Delorazepam Desalkylflurazepam	2,400 6,000 6,000 NOCLONAZEF 4,000 4,000 4,000 1,600 4,000 0,000 0,000 2,000	Temazepam 7-Aminoclonazepam 7-Aminoclonazepam Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Nordiazepam 7-Aminoclonazepam AM (7-ACL 100) Flunitrazepam RS-Lorazepam glucuronide Norchlordiazepoxide Norchlordiazepoxide Norchlordiazepam Temazepam Temazepam 7-Aminoclonazepam (CFYL 500) Fentanyl Ramifentanil Butyl fentanyl (CFYL 250)	9,000 300 2,000 1,800 3,000 10,000 6,000 200 1,000 900 1,500 5,000 3,000 100 100 100 150

(±)cis-3-Menthylfentanyl	10,000 CAFFEINE (C	, ,	75
Coffeine		AF 1,000)	
Caffeine	1,000	AT 150\	
(+) Norpsaudoophodring HCl	CATHINE (C	(+)3,4-Methylenedioxyamphe	
(+)-Norpseudoephedrine HCl (Cathine)	150	tamine (MDA)	100
d/l-Amphetamine	100	` '	100
Tryptamine		Methoxyphenamine	12,500
	TROPICAMIDE		12,300
	350	(TKO 330)	
	ALPRAZOLAM	(ALD 100)	
Benzodiazepines	l	i i	200
a-hydroxyalprazolam	1,500	·	3,000
	900	· '	200
Bromazepam Chlordiozopovido			6.000
Chlordiazepoxide	900		-,
Clobazam	200	'	200
Clonazepam	500	Norchlordiazepoxide	100
Clorazepatedipotassium	500	'	900
Delorazepam	900	'	300
Desalkylflurazepam	200		100
Diazepam	300		3,000
		Alprazolam	100
	REGABALIN (F	PGB 50,000)	1
Pregabalin	50,000		
	PREGABALIN	(PGB 500)	
Pregabalin	500		
	ZALEPLON (2	ZAL 100)	
Zaleplon	100		
	CANNABINOL	(CNB 500)	
cannabinol	500	Δ ⁹ -THC	10,000
11-nor-∆ ⁹ -THC-9 COOH	300		
(GABAPENTIN (GAB 2,000)	
	2,000		
	GABAPENTIN (GAB 5,000)	•
	5,000		
•	TRAZODONE	(TZD 200)	
Trazodone	200		
	ARISOPRODOL	(CAR 2.000)	
	2,000		
	ARISOPRODOL	(CAR 1 000)	
	l	. (OAN 1,000)	
	1,000	L (CAR 500)	
	ARISOPRODO 500	L (OAK 300)	
		(ABB/I/2 40)	
	B-PINACA/K3 (
AB-PINACA		AB-PINACA 5-Pentanoic	10
AB-PINACA 5-hydroxypentyl	10		10
AB-PINACA 4-hydroxypentyl	10,000		5,000
UR-144 5-hydroxypentyl	10,000		10,000
APINACA 5-hydroxypentyl	10,000	ADB-PINACA Pentanoic Acid	10
ADB-PINACA N-(5-hydroxypentyl)	30	5-fluoro AB-PINACA	30
	50	N-(4-hydroxypentyl)	JU
5-fluoro AB-PINACA	25		
	UR-144/K	4 (25)	
JR-144 5-Pentanoic acid	25	UR-144 4-hydroxypentyl	10,000
JR-144 5-hydroxypentyl			2,000
5-fluoro		ADB-PINAC	
AB-Pinaca N-(4-hydroxypentyl)	10,000	N-(4-hydroxypentyl)	>10,000
AB-PINACA 4-hydroxypentyl	>10,000	, ,, , ,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
		OTP 1 000)	
	QUETIAPINE ((
	QUETIAPINE (C		10 000
		Norquetiapine	10,000

	KRATOM (K	RA 300)	
Mitragynine	300	7-hydroxymitragynine	>50,000
	TILIDINE (1	TLD 50)	
Nortilidine	50	Tilidine	100
ALPHA-PYRROLIC	INOVALEROPI	IENONE (α-PVP 2,000)	
	2,000		
		OPHENONE (α-PVP 1,000)	
Alpha-Pyrrolidinovalerophenone	1,000		
	1	ROPHENONE (α-PVP 500)	
Alpha-Pyrrolidinovalerophenone	500		
		PHENONE (α-PVP 300)	
Alpha-Pyrrolidinovalerophenone	300	0.400)	
	ESCALINE (ME	S 100)	
Mescaline	100	C 200)	
Mescaline	BOO (ME	S 300)	
	PAVERINE (PA	D 500)	
Papaverine	500	Diflunisal	1,000,000
Methortrexate	65,000	Methedrone	500,000
Pragablin	500,000	Phenelzine	8,000
Quinine	4,000	Hericizine	0,000
	PENTADOL (TA	P 1 000)	
3-((1R,2R)-3-(dimethylamino)-1-		1 1,000)	
ethyl-2-methylpropyl)phenol	1,000		
	CITALOPRAM	(CIT 500)	
Desmethylcitalopram	500		
	F-KETAMINE (F	KET 1,000)	
2-(2-fluorphenyl)-2-methylamino-			
cyclohexanone	1,000		
	RISPERIDONE	(RPD 150)	•
Risperidone	150		
	COPOLAMINE	(SCOP 500)	-
Scopolamine	500	Atropine	3,000
N, N-DIN	METHYLTRYPT.	AMINE (NND 1,000)	
N, N-Dimethyltryptamine	1,000		
MIF	RTAZAPINE (M	TZ 500)	
N-Desmethylmirtazapine	500	Mirtazapine	500
OL	ANZAPINE (OZI	P 1,000)	
Olanzapine	1,000		
HYDR	OMORPHONE ((HMO 500)	
Hydromorphone	500	Morphine	200
Codeine	120	Ethylmorphine	120
Hydrocodone	500	Morphine	250
,		3-β-D-Glucuronide	
Levorphanol	2,000	Oxycodone	125,000
Normorphine	125,000	Norcodeine	31,200
Oxymorphone	125,000	Nalorphine	50,000
Thebaine	10,000	Diacetylmorphine (Heroin)	250
6-Monoacetylmorphine	120		
	OMORPHONE (1
Hydromorphone	300	Morphine	120
Codeine	75	Ethylmorphine	75
Hydrocodone	300	Morphine	150
,		3-β-D-Glucuronide	
Levorphanol	1,200	Oxycodone	75,000
Normorphine	75,000	Norcodeine	18,700
Oxymorphone	75,000	Nalorphine	30,000
Thebaine 6 Managastulmorphina	6,000	Diacetylmorphine (Heroin)	150
6-Monoacetylmorphine	75 OMORRHONE	(HMO 350)	
	OMORPHONE		100
Hydromorphone Codeine	250	Morphine Ethylmorphine	100
Codeine Hydrocodone	60 250	Ethylmorphine Morphine	125
rydrocodone	250	Morphine	125

		3-β-D-Glucuronide	
Levorphanol	1,000	Oxycodone	62,500
Normorphine	62,500	Norcodeine	15,600
Oxymorphone	62,500	Nalorphine	25,000
Thebaine	5,000	Diacetylmorphine (Heroin)	125
6-Monoacetylmorphine	60		

Effect of Urinary Specific Gravity

Fifteen (15) urine samples of normal, high, and low specific gravity ranges (1.005-1.045) were spiked with drugs at 50% below and 50% above cut-off levels respectively. The Multi-Drug Rapid Test was tested in duplicate using fifteen drug-free urine and spiked urine samples. The results demonstrate that varying ranges of urinary specific gravity do not affect the test results.

Effect of Urinary pH

The pH of an aliquoted negative urine pool was adjusted to a pH range of 5 to 9 in 1 pH unit increments and spiked with drugs at 50% below and 50% above cut-off levels. The spiked, pH-adjusted urine was tested with the Multi-Drug Rapid Test. The results demonstrate that varying ranges of pH do not interfere with the performance of the test.

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free urine or drug positive urine containing above related calibrator substances. The following compounds show no cross-reactivity when tested with the Multi-Drug Rapid Test at a concentration of 100 μ g/mL.

Non Cross-Reacting Compounds

Acetophenetidin	Cortisone	Zomepirac	Quinidine
N-Acetylprocainamide	Creatinine	Ketoprofen	Quinine
Acetylsalicylic acid	Deoxycorticosterone	Labetalol	Salicylic acid
Aminopyrine	Dextromethorphan	Loperamide	Serotonin
Amoxicillin	Diclofenac	Meprobamate	Sulfamethazine
Ampicillin	Diflunisal	Isoxsuprine	Sulindac
I-Ascorbic acid	Digoxin	d,I-Propanolol	Tetracycline
Apomorphine	Diphenhydramine	Nalidixic acid	Tetrahydrocortisone,
Aspartame	Ethyl-p-aminobenzoate	Naproxen	3-acetate
Atropine	β-Estradiol	Niacinamide	Tetrahydrocortisone
Benzilic acid	Estrone-3-sulfate	Nifedipine	Tetrahydrozoline
Benzoic acid	Erythromycin	Norethindrone	Thiamine
Bilirubin	Fenoprofen	Noscapine	Thioridazine
d,I-Brompheniramine	Furosemide	d,I-Octopamine	d,I-Tyrosine
Cannabidiol	Gentisic acid	Oxalic acid	Tolbutamide
Chloral hydrate	Hemoglobin	Oxolinic acid	Triamterene
Chloramphenicol	Hydralazine	Oxymetazoline	Trifluoperazine
Chlorothiazide	Hydrochlorothiazide	Papaverine	Trimethoprim
d,I-Chlorpheniramine	Hydrocortisone	Penicillin-G	d,I-Tryptophan
Chlorpromazine	o-Hydroxyhippuric acid	Perphenazine	Uric acid
Cholesterol	3-Hydroxytyramine	Phenelzine	Verapamil
Clonidine	d,l-Isoproterenol	Prednisone	

[ALCOHOL PERFORMANCE CHARACTERISTICS]

The detection limit on the **Urine Alcohol Rapid Test** is from 0.02% to 0.30% for approximate relative blood alcohol level. The cutoff level of the **Urine Alcohol Rapid Test** can vary based on local regulations and laws. Test results can be compared to reference levels with color chart on the foil package.

[ALCOHOL ASSAY SPECIFICITY]

The Urine Alcohol Rapid Test will react with methyl, ethyl and allyl alcohols.

[ALCOHOL INTERFERING SUBSTANCES]

The following substances may interfere with the **Urine Alcohol Rapid Test** when using samples other than urine. The named substances do not normally appear in sufficient quantity in urine to interfere with the test.

- A. Agents which enhance color development
- Peroxidases
- Strong oxidizers
- B. Agents which inhibit color development
 - Reducing agents: Ascorbic acid, Tannic acid, Pyrogallol, Mercaptans and tosylates, Oxalic acid, Uric Acid
 - Bilirubin

- L-dopa
- L-methyldopa
 Methampyrone

[BIBLIOGRAPHY]

- 1. Tietz NW. Textbook of Clinical Chemistry. W.B. Saunders Company. 1986; 1735.
- 2. B. Cody, J.T., "Specimen Adulteration in drug urinalysis. Forensic Sci. Rev., 1990, 2:63.
- 3. C. Tsai, S.C. et.al., J. Anal. Toxicol. 1998; 22 (6): 474

- Hawks RL, CN Chiang. Urine Testing for Drugs of Abuse. National Institute for Drug Abuse (NIDA), Research Monograph 73, 1986.
- Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 6th Ed. Biomedical Publ., Foster City,CA 2002.

Number: 14601103703 Revision date: 2023-10-10